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General Introduction
1. Introduction
This dissertation deals with original research results obtained from investigations on the
role and the predictive value of stimulus intensity dependent ERP components in the
pharmacotherapy of major depressive disorder (MDD). The Intensity Dependence of
Auditory Evoked potentials (IDAP) is the key parameter that has been assessed in the
five clinical studies which have been performed by our research group and are
presented here.
This general introduction starts with a concise overview of the epidemiology, clinical
characteristics and current theories on the etiology and pathophysiology of depression.
Subsequently, certain aspects of the pharmacological treatment with antidepressants,
with special attention to existing strategies and methods of treatment efficacy
prediction, are described followed by an overview of the general methodology of the
electroencephalography (EEG) and of event related potentials (ERP). Furthermore,
methodological assessment strategies of the IDAP particularly with regard to aspects of
reliability are evaluated. Finally, the aims of the presented studies will be introduced.
2. Major depressive disorder
Major depressive disorder belongs to the most common mental diseases in Europe and
in the United States. The European Study of the Epidemiology of Mental Disorders
(ESEMeD) analyzed diagnostic interviews of a random sample of non-institutionalized
inhabitants from Belgium, France, Germany, Italy, The Netherlands and Spain aged 18
years or older (n = 21425). This study revealed that 14 per cent reported a lifetime
history of any mood disorder of whom 4.2 per cent reported any mood disorder in the
last year. Major depression and specific phobia were the most common single mental
disorders (Alonso et al., 2004). For the United States, the National Comorbidity Survey
Replication (NCS-R) revealed a lifetime prevalence of 16.2 per cent and a 12-month
prevalence of 6.6 per cent for major depressive disorder (Kessler et al., 2003). Bijl et al.
(1997) found a lifetime prevalence of major depressive disorder of 15.4 per cent in the
Dutch population.
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According to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
American Psychiatric Association, 1994), major depressive disorder is characterized by a
single major depressive episode or several recurrent episodes in individuals without a
history of mixed, hypomanic or manic episodes. The DSM-IV defines 5 of 9 commonly
observed symptoms as a minimum criterion for the diagnosis of a major depressive
episode. During the same 2-week period at least one of these symptoms must be either
(1) depressed mood or (2) loss of interest or pleasure. Further symptoms are: (3)
significant weight loss when not dieting or weight gain, (4) insomnia or hypersomnia (5)
psychomotor agitation or retardation, (6) fatigue or loss of energy, (7) feelings of
worthlessness or inappropriate guilt, (8) diminished ability to think or concentrate, or
indecisiveness, (9) recurrent thoughts of death, recurrent suicidal ideation. The
symptoms are present permanently or almost daily, cause significant impairment in
social, occupational, or other important areas of functioning and are not due to the
direct physiological effects of a substance or a general medical condition.
Van Praag (1998) pointed out that the wide use of the DSM more or less led to a
disappearance of the syndromal differentiation from the diagnosis of depression. The
major constructs of affective disorders represented by the DSM (major depression and
dysthymia) cover a variety of syndromes. According to van Praag (1998), the diagnostic
differentiation of depressive syndromes is of enormous scientific value in biological
psychiatry and psychopharmacology, because the etiological and syndromal
heterogeneity of the major depressive disorder concept constrains the demonstration of
the specificity of a given compound. Furthermore, van Praag (1998) suggests the
formulation of hypotheses regarding the relationships between personality structure
and depressive syndromes and the systematic analysis of psychological dysfunctions
constituting the depressive syndrome.
2.1 The Etiology of depression
The multifactorial etiology of depression is widely accepted, but there is no agreement
over the exact contributional value of psychosocial, neurobiological and genetic factors.
2.1.1 Neurobiological factors
Disturbances in various neuroendocrine and neurotransmitter systems have been
associated with the pathophysiological mechanisms that are assumed to contribute to
the origin of depressive disorders, e.g. in the glutamatergic, cholinergic, GABAergic
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systems and the hypothalamic-pituitary-thyroid axis (HPT). Mainly the discussion of the
role of the monoaminergic system and the hypothalamic-pituitary-adrenal axis (HPA) has
a long tradition and will be introduced here.
The monoamine hypothesis
In the 1960s, the hypothesis was postulated that a central nervous (synaptic) deficit of
one or more monoamine neutransmitters (serotonin, norepinephrine and dopamine)
might be the neuronal basis of depressive disorders (Bunney and Davis, 1965;
Schildkraut, 1965; van Praag, 1970). Findings in the 1950s that the depletion of central
nervous monoamine stores by reserpin (antihypertensivum) was accompanied by
symptoms of depression (Shore et al., 1955) and that drug induced elevation of
monoamnine levels in the brain by iproniazid (tuberculostaticum) and by imipramine
had an antidepressive effect (Kline,1958; Kuhn,1958), formed the basis for the
monoamine hypothesis of depression.
The inhibition of the monoamine oxydase and the transporter mediated reuptake of
serotonin and norepinephrine were assumed to be the most important mechanisms of
action of antidepressive agents. A revised monoamine theory suggested that the
monoamine systems are only modulating "other" brain neurobiologic systems which
have a more primary role in depression (Heniger et al., 1996, review in: Delgado and
Moreno, 2000).
From the late 1960s, a deficit in serotonin (5-HT) metabolism as a potentially underlying
mechanism in the pathophysiology of at least a subgroup of depression became the
focus of neurobiological research. The major metabolite of 5-HT, 5-hydroxyindoleacetic
acid (5-HIAA), is found in the cerebrospinal fluid (CSF) as well as in the brain itself. Low
CSF 5-HIAA, thus, suggests a decrease of 5-HT metabolism in the central nervous system
(CNS). Van Praag and Korf (1971) described a lowering of cerebrospinal fluid (CSF)
concentration of 5-HIAA in a sample of depressive subjects. Various classes of
antidepressants as well as electroconvulsive treatment improve the efficiency of
serotonergic transmission, particularly of 5-HT1A receptor-mediated transmission, either
by sensitization of postsynaptic 5-HT receptors or by desensitization of presynaptic 5-HT
receptors that normally reduce the release of 5-HT in the synaptic cleft or inhibit the
firing rate of the 5-HT neuron (Blier and De Montigny, 1994). The role of 5HT-
metabolism in the pathophysiology of depression has also been investigated by the
tryptophan-depletion method. Tryptophan is an essential amino acid and the precursor
of 5-HT. Thus, a shortage of tryptophan leads to a deficiency of 5-HT. Such a state can be
generated by ingesting a mixture of amino acids, devoided of tryptophan and rich in
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competing amino acids. This strategy has been shown to lead to a decrease of 5-HIAA in
the CSF (Williams et al., 1999) and to a substantial lowering of brain 5-HT in animals
(Moja et al., 1989). Applied to healthy volunteers, this procedure leads to mood
lowering (Young et al., 1985). Furthermore, depletion of 5-HT induces a relapse in
depressed patients who were in remission after treatment with 5-HT specific
antidepressants (Delgado and Moreno, 2000). Van Praag (1992) demonstrated that a
low CSF 5-HIAA in depressive individuals did not disappear after remission of the
depression and might thus be a neurobiological trait-marker.
Disturbances of 5-HT receptors are another important mechanism that appears to be of
pathophysiological relevance in depression. The 5-HT system operates via at least 15,
probably function-specific, 5-HTreceptors (Van Praag, 2004). They are divided in seven
subtypes, named 5-HT1, 5-HT2...5-HT7 receptors. The 5-HT1 receptor family is
subdivided into four subgroups 5-HT1A up to 5-HT1D, the 5-HT2 family counts three
subtypes: 5-HT2A up to 5-HT2C receptors. In humans, 5-HT receptors have been
predominantly studied with challenge tests. Indirect 5-HT agonists have been used such
as the 5-HT precursors tryptophan and 5-HTP, as well as fenfluramine, a 5-HT releaser
and inhibitor of its reuptake (Newman et al., 1998). The secretion of prolactin and
adrenocorticotrophic hormone (ACTH) by the pituitary gland and of cortisol by the
adrenal cortex have been mostly used as serotonergically mediated variables. Most of
these studies reported blunting of the hormonal responses to indirect 5-HT agonists in a
subgroup of depression (Ansseau, 1997; Newman et al., 1998), indicating down-
regulation of 5-HT receptors. The prolactin responses to fenfluramine and to the
selective serotonin reuptake inhibitor (SSRI) citalopram remained blunted in recovered
patients (Florey et al., 1998). These findings suggest that some aspects of impaired
serotonergic transmission are trait-related phenomena.
A widespread reduction in 5-HT1A receptor binding was reported in patients with major
depression, both presynaptically in the raphe nuclei and postsynaptically, i.e. in several
cortical regions (Drevets et al., 1999; Sargent et al., 2000). As low 5-HT1A receptor
binding did not increase after clinical remission of depression, these disturbances might
be regarded as trait-marker and therefore represent a neurobiological risk factor for
depression. Additional support for the hypothesis that 5-HT1A receptor disturbances are
involved in the pathophysiology of depression or certain subtypes of depression has
been obtained from animal data. In animal models of depression, highly selective 5-
HT1A receptor agonists possess antidepressant properties (Mayorga et al., 2001).
HPA axis hyperactivity hypothesis
Although studies over the last 40 years have demonstrated that hyperactivity of the
hypothalamic-pituitary-adrenal axis is one of the most consistent neurobiological
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findings in the research of depressive disorders, there is no agreement regarding the
underlying mechanisms. In the 1950s, elevated plasma cortisol levels in indivuals
suffering from a depressive state were described by Board et al. (1956). Further studies
revealed that patients suffering from depressive disorders showed a reduced
suppression of cortisol secretion by the adrenal cortex in response to dexamethasone,
an elevated cortisol secretion in response to the adrenocorticotropic hormone (ACTH)
and a hypersecretion of corticotropin-releasing hormone (CHR), which stimulates ACTH
secretion (Holsboer and Barden, 1996; McQuade and Young, 2000). An impairment of
the glucocorticoid receptor system in HPA axis sensitive structures and the
hippocampus, resulting in a dysregulation of the feedback inhibition by endogenous
corticosteroids may explain the HPA axis hyperactivity in depression (for review see:
Pariante and Lightman, 2008).
Genetic influences
A medline search based metanalysis of studies on the genetic epidemiology of major
depression revealed that the heritability of this disturbance probably ranges from 31%
to 41% (Sullivan et al., 2000). It is assumed that mainly alterations in the expression of
neurotransmitters, neuropeptides and receptors rather than structural gene changes
underly genetic influences, which might be relevant in the origin of depression. This
assumption is also reflected by the concept of gene-environment interaction ,meaning
that genetic vulnerability to depression comes to expression only in individuals exposed
to specific environmental factors, e.g. emotional stress (Sullivan et al., 2000). Studies of
the interaction of the serotonin transporter 5-HTTLPR polymorphism genotype and
environment on the development of depression in aldulthood have suggested a role for
both childhood maltreatment and stressful life events. Childhood maltreatment might
trigger early changes in brain function associated with the polymorphism explaining the
link of such negative events with adult depressive episodes by an increased vulnerability
for stressful life events (for review see: Brown and Harris, 2008).
2.1.2 Psychosocial factors
The etiological impact of stressful life events, economic status, social relationships and
personality on the depressive disorders has been investigated extensively, but there are
hardly theoretical concepts, that have been widely accepted. The personality model of
Cloninger, which has been established in 1987 (Cloninger, 1987), has been linked with
the individual risk of developing a depressive disorder. A high score of Harm Avoidance,
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which is defined as the tendency to respond intensely to aversive stimuli, was found to
increase the susceptibility to depressive disorders (Cloninger, 1987). Temperament
following Cloningers personality model was also identified as a predictive factor of
treatment succes in 50 % of a patient sample suffering from severe depressive disorder
unter treatment with clomipramine and desipramine (Joyce et al., 1993).
3. Pharmacotherapy with antidepressants
The pharmacological treatment of depressive disorders started in the 1950s after the
discovery of tricyclic antidepressants (TCA) and monoamine oxydase inhibitors (MAO-
Inhibitors). Most antidepressants primarily enhance norepinephrine (NE), dopamine
(DA) and serotonin (5-HT) activity in brain, although their antidepressive effect is likely
to be modulated by other neurotransmitter and neurohormonal systems such as the
HPA axis (Nemeroff and Owens, 2004). MAO-Inhibitors have been shown to be effective
antidepressants. They prevent the catabolism of NE, DA and 5-HT neurotransmitters, but
their use is limited due to the risk of severe adverse events such as serotonin syndrome
and hypertensive crises. NE-selective antidepressants, such as the TCA desipramine and
the selective NE re-uptake inhibitor (NRI) reboxetine, have been shown to be effective in
the treatment of MDD. In a review by Montgomery et al. (1997) istwas concluded that
reboxetine may have an equipotent antidepressant efficacy as compared to TCAs and to
selective serotonin re-uptake inhibitors (SSRIs). Selective antidepressants such as
serotonin reuptake inhibitors preserve the ability to block the serotonin (5HT) reuptake,
but have no effect on e.g. M1, H1 or α1 receptors, which increases their tolerability
compared to TCAs. Thus, SSRIs have become established as the first-line therapy for the
treatment of MDD although many patients (28 - 55%) fail to respond sufficiently to this
class of compounds (Trivedi et al., 2006). Dual-acting antidepressants (SNRIs), such as
duolextine, have shown similar but not superior rates of response to the SSRIs (Detke et
al., 2004).
As a consequence of the assumed role of the HPA axis in the pathophysiology of
depression, antagonistic compounds to stress-hormones have been studied in animals
and humans with regard to their antidepressive potential. In animals, such compounds
reduce a repertoire of behaviours associated with anxiety (Basso et al., 1999; Arborelius
et al., 2000). Recently, CP-316,311, a selective nonpeptide antagonist of corticotropin-
releasing hormone type 1 (CRH(1)) receptors, was randomly assigned to a sample of
patients with recurrent major depression in a 6-week fixed-dose, double-blind placebo-
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and sertraline-controlled trial. Although CP-316,311 was safe and well tolerated in this
study population, it failed to demonstrate any efficacy in the treatment of major
depression (Binneman et al., 2008).
It is becoming increasingly evident that depression is a heterogeneous, systemic illness,
involving an array of different neurotransmitters, neurohormones, and neuronal
pathways. Considering that a generally superior mode of antidepressive action has not
been found during more than half a century, reliable prediction methods of treatment
response to seronotonergic versus non-serotonergic antidepressants could be of
considerable clinical value in order to avoid an unnecessarily delayed onset of
antidepressant effect.
4. The stimulus intensity dependence of ERP components (IDAP)
4.1 Background: The methodology of EEG and ERP
Electroencephalography (EEG) is a diagnostic method based on the measurement of
electrical activity produced by the brain as recorded from electrodes placed on the scalp.
The electrical activity of the brain derives from microanatomic structures, e. g. currents
within a single dendrite of a single neuron, which reach the scalp surface. Resulting
voltage differences on the scalp can be recorded as the electroencephalogram. EEG
electrodes positioned on different locations at the surface of the head receive electrical
signals which can be amplified and digitalized for later processing (figure 1).
The scalp EEG measures the summed activity of post-synaptic currents. The result is a
flow of ions into or out of the dendrite, which is followed by compensatory currents in
the extracellular space. These extracellular currents generate EEG voltages. Thus, a
surface EEG reading is the summation of the synchronous activity of thousands of
neurons that have similar spatial orientation, radial to the scalp. As currents that are
tangential to the scalp cannot be detected by this method, the EEG benefits from the
parallel, radial arrangement of apical dendrites in the cortex. Because voltage fields
decrease with the fourth power of the radius, activity from deep sources is more difficult
to detect than currents near the skull.
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Figure 1
A typical EEG laboratory, with the subject to the left and examples of EEG recordings to the right.
Only two electrode leads are shown here, but the principle is the same when more leads are
added. RH = right hemisphere, LH left hemisphere, amp = amplifier. The settings for the filters are
only examples of possible settings. (Hugdahl, Kenneth, 1995. Psychophysiology. The mind-body
perspective. Cambridge, MA & London, England; Harvard University Press.)
Scalp EEG activity oscillates at multiple frequencies having different characteristic spatial
distributions associated with different states of brain functioning. These oscillations
represent synchronized activity over a network of neurons (Hughes and John, 1999).
In conventional scalp EEG, the recording is obtained by placing electrodes on the scalp
with a conductive gel or paste, usually after preparing the scalp area by light abrasion to
reduce impedance due to dead skin cells. Many systems typically use electrodes, each of
which is attached to an individual wire. Some systems use caps (figure 2) or nets into
which electrodes are embedded; this is particularly common when high-density arrays of
electrodes are needed.
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Figure 2
EEG Cap (32 channels)
Electrode locations and names are specified by the International 10–20 system for most
clinical and research applications (figure 3). This system ensures that the naming of
electrodes is consistent across laboratories. In most clinical applications, 19 recording
electrodes (plus ground and system reference) are used. Each electrode is connected to
one input of a differential amplifier (one amplifier per pair of electrodes); a common
system reference electrode is connected to the other input of each differential amplifier.
These amplifiers augment the voltage between the active electrode and the reference
(typically 1.000–100.000 times, or 60–100 dB of voltage gain).
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Figure 3
32-channel EEG: positions of electrodes (10 -20 system)
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Figure 4
Normal (calm) EEG
In digital EEG systems the amplified signal is digitized via an analog-to-digital converter,
after being passed through an anti-aliasing filter. Analog-to-digital sampling typically
occurs at 256-512 Hz in clinical scalp EEG; sampling rates of up to 10 kHz are used in
some research applications.The digital EEG signal is stored electronically and can be
filtered for display. Typical settings for the high-pass filter and a low-pass filter are 0.5-1
Hz and 35–70 Hz, respectively. The high-pass filter typically filters out slow artifacts, such
as electrogalvanic signals and movement artifacts, whereas the low-pass filter filters out
high-frequency artifacts, such as electromyographic signals.
A typical adult human EEG signal (figure 4) is about 10µV to 100 µV in amplitude when
measured from the scalp and is about 10–20 mV when measured from subdural
electrodes.The EEG is typically described in terms of (1) rhythmic activity and (2)
transients. The rhythmic activity is divided into bands by frequency. To some degree,
these frequency bands are a matter of nomenclature (i.e., any rhythmic activity between
8-12 Hz can be described as "alpha"), but these designations were chosen because
rhythmic activity within a defined frequency range was noted to have a typical
distribution over the scalp or a certain biological significance. Most of the cerebral
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signals observed in the scalp EEG falls in the range of 1-20 Hz. Under standard clinical
recording techniques, activity below or above this range is likely to be artefactual .
Cognitive research performed with EEG most frequently makes use of the event-related
potential (ERP) technique. Most ERP paradigms involve a subject being provided with a
stimulus to react to, either overtly or covertly (figure 5). Depending on the hypothesis
tested, there are at least two conditions that vary in some manner, e.g. high versus low
tone freuency. As the stimulus-response is going on, an EEG is being recorded from the
subject. The ERP is obtained by averaging the EEG signal from each of the trials under a
certain condition; averages from one stimulus-response condition can then be compared
with averages from the other stimulus-response condition(s). Stimuli of various sensory
qualities can be applied albeit that visual and auditory stimuli are most frequently used.
ERPs to auditory stimulation consist of early and late components (figure 6). There are
three major early components: the electrically positive P1 component at about 50 ms
following stimulus onset, the negative N1 component at about 100 ms and the positive
P2 component at about 200 ms. Furthermore, the P300 or P3 component, which occurs
300 ms (mean) after stimulus onset, is the most important late component in sensory
evoked potentials. Enhancement of auditory stimulus intensities, are mainly reflected
by increases in the amplitudes of the P1/N1, N1, N1/P2 and the P2. Thus, interindividual
differences in the stimulus intensity dependence of ERP components (IDAP) are
phenomena that predominantly, refer to early ERP components. Typically, several
stimulus intensities are used to elicit amplitude changes, which can be transformed into
slope values that give the amplitude change in µV per 10/dB (Beauducel et al., 2000).
4.2 The stimulus intensity dependence of ERP components (IDAP)
Research on the stimulus intensity dependence of ERP components has a long tradition,
but broad scientific interest arose only 15 years ago when Hegerl and Juckel (1993)
introduced their hypothesis and theory of the IDAP as an indicator of central
serotonergic neurotransmission (Hegerl and Juckel, 1993).
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Figure 5
Schematic depiction of the measurement and averaging of event-related potentials. Singular
"waves" temporally associated with a specific experimental event are usually labeled according to
their polarity and latency from the triggering event. (e.g. N100 = negatively poled ERP with peak
latency at roughly 100 milliseconds; P300 = positively poled ERP with peak latency at roughly 300
milliseconds). Negative potential deflections are often presented facing upwards (modified from
MPI for neurological Research, Cologne).
Figure 6
Auditory evoked potential with early (P1, N1, P2) and late components (P3).
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Neurophysiology
An ERP results mainly from the summation of cortical excitatory and inhibitory
postsynaptic potentials triggered by the release of neurotransmitters like GABA and
glutamate. An ERP is therefore likely to directly reflect functional aspects of these
neurotransmitters. Furthermore, it may indirectly reflect modulating effects of
neurotransmitters like serotonin and acetylcholine on cortical functioning. The highest
concentrations of cortical serotonin have consistently been found in the primary sensory
cortices, especially in the primary auditory cortex. The theory of Hegerl and Juckel
(1993) postulates that serotonergic neurotransmission modulates sensory processing in
the auditory cortex, mainly in the primary auditory cortex. Serotonergic projections to
the auditory cortices might modulate neuronal activity in an initial stage of signal
processing in the cortex. The observed loudness dependence of auditory ERP
components is therefore assumed to occur as a consequence of cortical serotonergic
modulatory effects. An increased serotonergic neurotransmission, for example as a
consequence of a high firing rate of serotonergic neurons in the raphe nuclei, is
assumed to result in an only small increase in the auditory evoked cortical response with
increasing loudness (intensity) of the stimuli (tones), or in other words, in a low IDAP.
The inverse relationship between central nervous serotonergic activity and IDAP is
assumed to exist vice versa as well.
Method
Although many studies found reliable results either for the N1/P2 derived IDAP or for
the N1 derived IDAP, it is still not definitely known which ERP component gives the best
correlation with central nervous serotonergic activity. The N1 or N1/P2-component of
the auditory evoked potential occurs about 70 – 200 ms after the stimuli, exhibits
pronounced interindividual differences in its loudness dependence, and can be reliably
observed. In the 1980s, intracranial recordings and lesion studies provided evidence that
the N1 and N1/P2 component is generated by primary as well as secondary auditory
cortices (for review see Vaughan an Arezzo, 1988).
The serotonergic modulation theory of the IDAP (Hegerl et al., 1994) results in the
following main assumption: a high IDAP is assumed to be mainly caused by low
serotonergic neurotransmission in the primary auditory cortex that is known to be highly
innervated with serotonergic neurons. According to Hegerl et al. (1993), the IDAP should
be ideally assessed in the primary auditory cortex. In human studies this can indirectly
be done by using multichannel-EEG combined with source analysis techniques such as
Brain Electrical Source Analysis (BESA; Gallinat and Hegerl, 1994; Scherg, 1990; Scherg
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and Von Cramon, 1986) or Low Resolution Electromagnetic Source Analysis (LORETA;
Mulert et al., 2002; Pascual-Marqui et al., 1994). By means of BESA, it has been
demonstrated that the scalp N1/P2 can be explained by two dipoles per hemisphere, a
radial and a tangential dipole (Hegerl et al., 1994). The latter accounts for most of the
variance and is located in the primary auditory cortex, whereas the former touches the
secondary cortex. Thus, dipole source analysis allows separating the influence of the
serotonergic modulated primary auditory cortex from other structures. However, dipole
source analysis requires special expertise and is often too time consuming and expensive
for clinical practice and even research. In clinical settings, low-cost, easy applicable, fast,
automated and objective methods are needed. This is perhaps the reason why there are
still many successful studies using only one or a few EEG channels at central sites, mostly
Cz (e.g. Carrillo-de-la-Pena et al.,2006; Gallinat et al., 2003). In the study by Dierks et al.
(1999), using an acute tryptophan depletion paradigm, a high correlation of the IDAP of
tangential dipoles with the IDAP at Cz was found.
Despite its wide acceptation, data on the reliability of the IDAP are limited, possibly for
two reasons. First, the visual modality was preferred in the beginning of intensity
dependence research, at that time usually called augmenting/reducing (Buchsbaum an
Pfefferbaum, 1971). This explains why most studies reporting reliabilities on single
channel intensity dependence, deal with results derived from visual stimuli. However,
visual and auditory intensity dependence are not clearly associated (Raine et al., 1981),
and the serotonin hypothesis as proposed by Hegerl and coworkers is exclusively based
on the auditory modality. Second, having focused to auditory intensity dependence
following the serotonin hypothesis by Hegerl, the majority of studies no longer reported
the reliability of single and multichannel IDAP, but only that of tangential and radial
dipoles. Dipole analyses in these studies revealed mostly good test–retest reliabilities for
the IDAP of the tangential dipole from r = .77 (Gohle, 2005) to r = .88 in a study by Hegerl
et al. (1994). The coefficients for the radial dipole were much lower, ranging from r = .38
for N1/P2 amplitude (Hegerl et al., 1994) to r = .66 (Carrillo-de-la-Pena, 2001).
Despite the above mentioned shortcomings, there are studies on the methodology of
IDAP in which single electrodes were applied and auditory stimuli were used. Most of
these studies detected reliabilities between r =.7 and .8. In a sample including 8 men and
16 women (mean age = 47, SD = 11), Beauducel et al. (2000) revealed a retest-stability of
the IDAP after about three weeks of .71, .77 and .59 at Cz, C3, C4, respectively. Applying
Principal Component Analysis (PCA) improved the reliability in this study to .78, .80 and
.76 at Cz, C3, C4, respectively. In a sample comprising 5 males and 16 women (18–23
years, mean age = 18.8; SD = 1.2), Carrillo-de-la-Pena (2001) found correlations of .79
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and .76 with an extraordinarily long test–retest interval of one year for the central
electrodes Fz and Cz, respectively. In a study by Hegerl et al. (1988), two retests in a
sample of 17 males and 16 females (19–63 years, mean = 40; SD = 13) were performed:
one retest after 20 min and another after three weeks. While the first revealed
reliabilities of .70, .58 and .53 for Cz, C3, C4, respectively, even higher reliabilities
coefficients of .74, .77, and .71 were found with the test–retest interval comprising three
weeks. In a study by Sandor et al. (1999), the stabilities were in a similar range of .71 to
.76 after 1, 2 or 24 hours, when the stimuli were presented with a fixed repetition rate.
However, in the same study variable interstimulus intervals revealed only a reliability
coefficient of .52 irrespective of the test–retest interval. These lower reliability
coefficients as found by Sandor et al. (1999) might be caused by a higher proportion of
men in the sample (4 women and 8 men; 24 ± 3 years). Friedman and Meares (1979b)
examined only males (N = 29; 18–30 years old; mean age not given) and found a
significant stability of r = .6 over one week for the N1/P2 slope. Another gender
homogeneous study by Debener et al. (2002) including 18 women between 19 and 34
years (M = 22.4, SD = 3.4) revealed stabilities of the N1/P2 slope between r = .56 and r =
.58. The results of the latter gender homogeneous studies demonstrated much lower
coefficients. It should be stressed, however that the EEGs of Debener et al. (2002) were
run in subjects fasting just before treatment within a cross-over placebo controlled
tryptophan depletion paradigm. This experimental condition might have caused more
state-related error variance than an usual IDAP test-retest paradigm. In summary, most
stability coefficients for single central electrodes in gender-mixed samples vary between
.7 and .8, while more homogeneous samples showed lower reliabilities.
Most of the above cited studies have limitations with respect to three factors that have
potential impact on reliability, namely gender, age and variability of IDAP parameters.
Females showed a higher IDAP in several studies (Bruneau et al., 1986; Camposano and
Lolas, 1992; Schwerdtfeger et al., 1999; Silverman et al., 1973). Age also impacts the
IDAP as a higher age generally seems to coincide with lower IDAP (Hegerl et al., 1994;
Siniatchkin et al., 2000). Thus, an age- and gender-heterogeneous sample might
generate artificially elevated test–retest reliabilities partly due to the constant factors of
age and sex from test to retest, assuming that every IDAP-correlated variable that
remains constant from test to retest could lead to an overestimation of test–retest
reliability.
In addition to the assumed confounding effects of age and gender, different
parameterizations of the IDAP might also influence the reliability. The most common
way to parameterize the IDAP seems to be the calculation of a linear regression of ERP
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amplitudes against stimulus intensities. The slope of this linear regression (called
‘‘amplitude-stimulus function slope’’ or ASF slope) indicates the linear amplitude change
with increasing stimulus intensity. Another slope (called median slope) does not require
linearity of the IDAP. It is calculated as the median of all possible slopes between pairs of
two amplitudes each. For example, if five intensities are used, then there are 10 possible
slopes between pairs of intensities from which the median is calculated. The reliability of
all slope measurements will depend on the reliabilities of the single evoked potentials at
each intensity from which the slope is calculated. These reliabilities of the amplitudes
are of special interest, as some studies dealing with the serotonin hypothesis of IDAP
abstain from calculating slopes but rely on the ERP amplitude derived from a single high
intensity stimulus (Manjarrez et al., 2005). Most studies describe test–retest reliabilities,
which indicate both stability of the IDAP over time and accuracy of measurement. Other
relevant reliability indices are the odd–even and split-half reliability. In the case of
evoked potentials, all sweeps are virtually the same. The comparison of the averaged
odd sweeps with the averaged even sweeps does not provide much information on
internal consistency or homogeneity, but instead gives information on the ability of the
paradigm to get a sufficient signal-to-noise ratio if only half of the sweeps are averaged.
Therefore, odd–even reliability will substantially depend on the length of the paradigm,
i.e. how many stimuli are presented. The split-half reliability compares the IDAP of the
first half of the testing session with the IDAP of the second half. Besides measurement
accuracy, the correlation coefficient between first and second half’s IDAP will be
influenced by time-on-task processes like habituation, fatigue and test anxiety that could
alter the ranking of interindividual differences in the IDAP. By comparing the split-half
and odd–even reliabilities, the influence of such time-on-task effects can be estimated.
Hensch et al. (2008) examined test–retest, split-half and odd–even reliabilities of the
IDAP and of single ERP amplitudes at central positions (Cz, C3, C4) simultaneously
(Hensch et al., 2008). The authors evaluated auditory-evoked potentials from 166
students, of whom 37 women and 25 men were retested after three weeks.
Furthermore, they compared two manners of IDAP slope calculation: the ASF slope
(based on linear regression) and the median slope. The possibly confounding effects of
age and gender were controlled for. Test–retest and odd–even reliabilities were
remarkably high at Cz in both females (r = .88/.86) and males (r = .82/.79). Reliabilities
were higher in women, higher with linear than median slopes and best at Cz. Hensch and
coworkers (2008) concluded that reliabilities, especially at Cz, can reach the same level
as previously reported by dipole-source-localization methods, if sufficient sweep
numbers are applied.
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Animal studies
Juckel et al. (1999) reported differential effects of microinjection of a 5-HT1A agonist
and a 5-HT1A antagonist into the dorsal raphe nucleus (DRN) on the intensity
dependence of auditory evoked potentials (AEP) recorded epidurally from the primary
and secondary auditory cortex in behaving cats. Recently, Wutzler et al. (2008)
performed in vivo measurement of cortical extracellular serotonin levels simultaneously
with the recording of auditory evoked potentials in the epidura of rats. Extracellular
serotonin levels in the primary auditory cortex were measured by in vivo microdialysis
before and after application of the selective serotonin reuptake inhibitor citalopram. The
increase of serotonin levels after citalopram application was significantly related to a
decrease of the IDAP of the N1 component (Wutzler et al, 2008).
Preclinical studies
Strobel et al. (2003) described an association of a functional polymorphism in the
promoter region of the serotonin transporter gene (5-HTTLPR) with the N1/P2 amplitude
intensity dependence. This result has been replicated by Hensch et al. (2006). Juckel et
al. (2007a) reported an association between a 5-HT
1B
receptor polymorphism and IDAP..
On the other hand, Debener et al.(2002) found no effects of acute tryptophan depletion
on AEP N1/P2 amplitude stimulus intensity function (ASF-slope) in a placebo controlled
trial in healthy women. Uhl et al. (2006), measured the IDAP in female subjects during
infusion of citalopram versus placebo before and for a period of up to 60 min after
drug/placebo administration, and performed dipole source analysis. They found no
significant change of the IDAP in response to citalopram compared to the placebo
condition. Finally, Norra et al. (2008) performed a tryptophan depletion test versus
placebo in healthy women and monitored tryptophan levels and mood states while
measuring the IDAP followed by dipole source analysis. Calculated IDAP slopes neither
differed significantly between treatments nor correlated with states of mood, suggesting
that the IDAP might reflect individual (trait) rather than state differences of serotonergic
neurotransmission.
Clinical studies
In clinical research, the role of the IDAP has been studied in several psychiatric
disturbances and diseases. Tuchtenhagen et al. (2000) and Croft et al. (2001) found an
elevated intensity dependence of auditory evoked dipole source activity in abstinent
ecstasy (MDMA) users and long-term MDMA abuse, respectively. Juckel et al. (2003)
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reported that the IDAP of the primary auditory cortex derived from dipole source
analysis in 25 in-patients suffering from schizophrenia is significantly decreased
compared to a healthy control group. Wang et al. (2006) described an elevation of the
IDAP in female patients with histrionic personality disorder. Furthermore, the IDAP was
found to be elevated in patients suffering from bipolar affective disorder (Brocke et al.,
2000) and from fibromyalgia (Carrillo-de-la-Pena et al., 2006). However, despite the
hypothesized pathophysiological role of serotonin in obsessive compulsive disorder,
Carrillo-de-la-Pena et al. (2000) could not demonstrate any difference between patients
and controls. Senkowski et al. (2003) described a significantly lower IDAP derived from
bilateral tangential dipoles in 31 medication-free patients with general anxiety disorder
in comparison to matched healthy control subjects.
The concept of the IDAP as an electrophysiological indicator of central serotonergic
neurotransmission in major depressive disorder with special relevance to treatment-
response to serotonergic versus non-serotonergic antidepressants and to other
medication that influence the serotonergic system, has been evaluated in several studies
(Gallinat et al., 2000; Juckel et al., 2004; Lee et al., 2005; Mulert et al., 2007, Guille et al.,
2008). At the time, however, we started our studies on the IDAP, the value of this
method in clinical psychiatric practice was still unclear.
Shortcomings and questions
At the start of our research program, there were no sufficient data on the predictive
value of the IDAP in the differentiated psychopharmacotherapy of depressive disorders.
Whereas earlier studies from 1990s evaluated the IDAP in samples of patients who were
treated with a variety of antidepressants during the period of the test procedures, we
performed two studies in groups of patients, who were exclusively treated with one
selective serotonergic or with one selective noradrenergic antidepressant, respectively.
In order to obtain a range of normal values, we measured the IDAP in a sample of
healthy subjects. These IDAP results were subsequently compared with those obtained
from a sample of unmedicated patients with major depressive disorder in order to learn
whether MDD is paralled by a general abnormality of the IDAP. In a further study, we
investigated whether there is a relationship between symptom clusters of MDD and the
level of the IDAP.
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5. Aims of the performed studies and outline of this thesis
The specific aims of the presented studies are the following:
1. To evaluate the predictive value of the of pre-treatment intensity dependent
auditory evoked ERP component (P1, N1, P2, P1/N1, N1/P2) amplitude slopes in
a sample of patients with major depression exclusively treated with the SSRI
citalopram.
2. To assess the predictive value of pre-treatment intensity dependent auditory
evoked ERP component (P1, N1, P2, P1/N1, N1/P2) amplitude slopes in a
sample of patients with major depression, who were exclusively treated with
the selective norepinephrine re-uptake inhibitor (SNRI) reboxetine.
3. To investigate whether the IDAP is mainly a state or a trait indicator of central
serotonergic neurotransmission, whether serotonergic and non-serotonergic
antidepressants differently influence the IDAP and whether the pre-treatment
IDAP changes during the course of treatment of MDD.
4. To investigate the hypothesis that unmedicated patients suffering from major
depression exhibit a higher IDAP compared to healthy control subjects.
5. To investigate the hypothesis that the IDAP is associated with certain
psychometrically assessed symptom clusters of depression and to identify,
describe and discuss those dimensions that are indirectly associated with a
favourable outcome to SSRI treatment as predicted by a strong IDAP.
Our research group evaluated the IDAP in patients suffering from MDD and in healthy
control subjects. We assessed the predictive value of the IDAP for treatment with the
SSRI citalopram (Chapter 2) as well as for treatment with the selective norepinephrine
re-uptake inhibitor reboxetine in MDD (Chapter 3). We compared the IDAP of auditory
ERP components in unmedicated patients with MDD with the results from healthy
controls (Chapter 4) and evaluated treatment effects of serotonergic and noradrenergic
antidepressants in MDD on the IDAP itself (Chapter 6). Furthermore, we studied
associations of certain clinical symptom clusters of MDD with the auditory ERP
components (Chapter 5). In Chapter 7 we discuss the results and present the final
conclusions of this thesis.
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1. Abstract
The intensity dependence of the auditory evoked N1 ERP component (IDAP) has
been suggested as an indicator of central serotonergic neurotransmission with
relevance to pharmacological treatment. Here we report results of a study
evaluating the IDAP in 16 in-patients fulfilling DSM-IV criteria for major depressive
episode in the course of treatment with the Selective Serotonin Reuptake Inhibitor
citalopram. Our data revealed a significant correlation between the intensity
slopes of the N1 amplitude prior to citalopram-treatment and treatment-response:
patients with higher intensity slopes of N1 amplitude showed a significantly
stronger decrease of HDRS-Score after citalopram-treatment than patients within
the lower intensity slope ranges. Our results indicate an association of N1
amplitude intensity dependence with response to antidepressant treatment with
citalopram.
2. Introduction
The search for reliable electrophysiological indicators of serotonergic dysfunction
in major depression with relevance for psychopharmacological therapy has
attracted scientific interest recently [5, 7, 16]. The involvement of serotonin in
auditory cortical processing has been demonstrated e.g. in studies examining the
effects of acute tryptophan depletion [11]. Amplitude changes of the N1 and the
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N1/P2 ERP component in response to different tone intensities have been
suggested as a correlative of central nervous serotonergic activity [3, 7, 10, 18, 21]
with a strong loudness dependent amplitude increase (“strong intensity
dependence”) presumably reflecting low serotonergic neurotransmission and vice
versa [10]. This psychophysiological finding might be of clinical relevance with
regard to the modulating role of serotonin in the pathogenetic concept of
depression [8] and of other psychiatric disorders [4, 19]. While first investigations
on the intensity dependence of sensory evoked potentials and their relation to
psychiatric disorders by Buchsbaum et al. (1968) and von Knorring et. al. (1978)
were based on the hypothesis of "augmenting/reducing" [3], recently the same
phenomenon has been described by different terms. As to the acoustic modality,
the term "IDAP" (intensity dependence of the cortical auditory evoked potentials)
is widely used, especially in the context of migraine research [15], whereas in the
context of psychiatric research the term "LDAEP" ("loudness dependence of the
auditory evoked potentials") has been suggested [5, 7].
As the auditory cortex belongs to those cortical areas with the highest density of
serotonergic fibers in brain [9], Juckel et al. examined the effects of microinjection
of a 5HT
1A
agonist and a 5HT
1A
antagonist into the dorsal raphe nucleus (DRN) on
AEP recorded epidurally from the primary and secondary auditory cortex in
behaving cats. Injection of a 5HT
1A
agonist (8-OH-DPAT), which inhibits the firing
rate of serotonergic DRN neurons, lead to a stronger intensity dependence of AEP
from the primary auditory cortex, whereas injection of a 5HT
1A
antagonist
(spiperone) reduced AEP intensity dependence compared to baseline[10]
Several studies corroborated the concept of the IDAP as an indicator of central
serotonergic neurotransmission. The concentration of 5-hydroxyindoleacetic acid
(main metabolite of serotonin) in cerebrospinal fluid was found to be inversely
correlated with the intensity dependence of sensory evoked potentials [21] and
serotonin agonists reduced the intensity dependence of the N1 amplitude [10, 20].
In patients under treatment with serotonin reuptake inhibitors (SSRI) Hegerl et al.
(1998) found high scores in the serotonin syndrome scale (SSS) to be associated
with low IDAP and vice versa [7]. Tuchtenhagen et al. (2000) reported a high
intensity dependence of auditory evoked dipole source activity in abstinent
ecstasy (MDMA) users indicating a decreased serotonergic activity [19]. Similar
results have been described by Croft et al. (2001) for long-term MDMA abuse [4].
Recently, Strobel et al. (2003) found a functional polymorphism in the promoter
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region of the serotonin transporter gene (5-HTTLPR) to be associated with the
N1/P2 amplitude intensity dependence [18].
Based on these findings the IDAP has been suggested as an psychophysiological
indicator of central serotonergic neurotransmission in depression with special
relevance to treatment-response to SSRI. Indeed, Paige et al. (1994) found
responders to different serotonergic antidepressants to show significantly higher
P2 amplitude slopes (as a function of stimulus intensity) prior to treatment than
nonresponders [14]. Gallinat et al. (2000) reported an association of pre-treatment
N1/P2 amplitude slope with treatment success as indicated by a decrease of
Hamilton scores after 4 weeks in patients treated with different SSRI (paroxetine,
sertraline, citalopram) [5].
The aim of our study was to assess the predictive value of pre-treatment intensity
dependent auditory evoked ERP component (P1, N1, P2, P1/N1, N1/P2) amplitude
slopes in a sample of patients with major depression exclusively treated with the
SSRI citalopram.
3. Method
Sixteen acutely depressed in-patients (DSM-IV: 296.2, 296.3, 296.5, 300.4; APA
1994), who were admitted consecutively to the Department of Psychiatry and
Psychotherapy of the University of Duisburg-Essen and considered as candidates
for an antidepressant medication with citalopram, were included in the study.
Patient characteristics are given in Table 1. Clinical symptoms of major depression
were assessed by means of psychiatric rating scales: Clinical Global Impression
(CGI) [13], Hamilton Rating Scale for Depression (HDRS, 21 items) [6] and Beck
Depression Inventory (BDI) [1]. Clinical ratings were performed by experienced
psychiatrists, who had no information on patients' ERP data. The total score of
HDRS had to be 20 at least.
Patients gave their informed written consent prior to their inclusion in the study.
The study was approved by the local ethics committee. ERP data were recorded
one day before the start of pharmacological treatment with citalopram (baseline).
The CGI, HDRS and BDI scores, were obtained at the day of ERP recordings and
Prediction of citalopram response
-48-
again after three weeks of treatment (D25). Pre-treatment antidepressants (eight
patients, non-SSRI) were stopped at least 2 days before the ERP recording. Central
neurological disorders, abuse of illicit drugs and alcohol dependence were
excluded, as was pre-treatment with electroconvulsive therapy. The auditory
threshold with respect to 1000 Hz tones was below 30 dB as measured by an
audiometer. Following the ERP-recording, patients were treated with citalopram
(range: 20 to 40 mg) for 25 (21 – 28) days. Concomitant medication with
antipsychotics, moodstabilizers, additional antidepressants were not allowed.
Concomittant benzodiazepine treatment (n=3) was restricted to a maximum dose
of 1.5mg lorazepam per day. Lorazepam was not given 12 hours before ERP-
recording.
Table 1
Subject characteristics
n 16
Age 39.38 (±14.5)
Gender (m/f) 5/11
Education (y) 13.0 (±2.6)
Nicotine (n; mg/d) 9; 12.9 (6.3)
Episodes of depression (n) 2.37(±1.7)
Duration (y) 8.3 (±7.3)
Dose of citalopram (Day 25) 37.5 (±10.0)
CGI (Baseline/25) 4.56 (±0.7)/3.9 (±0.8)
HDRS (Baseline) 25.13 (±3.5)/14.6 (±5.5)
BDI (Baseline) 29.50 (±12.5)/21.6 (11.0)
ERP data were recorded in a sound-attenuated and electrically shielded room and
subjects were seated in a comfortable armchair. Auditory stimulation was done in
two runs of 500 stimuli each with an interstimulus-interval randomized between
500 ms and 900 ms. Auditory stimuli of 1000 Hz, with 80 ms duration (10 ms rise /
fall) were presented at five intensities of 60, 70, 80, 90 and 100 dB sound pressure
level via TDH-39p headphones (Telephonics Inc.) in randomized order. Stimulus
presentation was generated by Neuroscan Stim 3.3 Software. Evoked potentials
were recorded from 27 scalp electrodes (extended international 10-20 system)
with linked earlobes as reference using a 32-channel EEG amplifier (Neuroscan
Inc.). Additionally, vertical and horizontal electro-oculogram (EOG) was recorded
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for offline artifact removal [17]. ERP data were recorded with a sampling rate of
500 Hz in the frequency range of 0.1 to 100 Hz. ERP data were offline filtered with
a 0.1 Hz to 30 Hz bandpass filter (Neuroscan Edit 4.1). EEG data were segmented
into periods of 600 ms starting 100 ms prior to stimulus onset. Segments with
artifacts exceeding +/- 50 µV were rejected from further analysis. ERP averages
were computed for each stimulus intensity level. Mean sweep numbers ranged
between 117.5 and 133.4 sweeps for intensities between 60 dB up to 100 dB.
Amplitudes of the N100 and the P200 components were computed from electrode
Fz, Fcz, Cz, C3 and C4. Intensity slopes (linear regression) were computed for the
P1, N1, P2 amplitudes and the P1/N1 and N1/P2 peak to peak amplitudes. All
statistical analyses were performed using SPSS 11.5.
4. Results
Psychiatric rating scores significantly improved from baseline to retest after 25
days of treatment: HDRS total score decreased from 25.1 (±3.5) to 14.6 (±5.5), BDI
total score from 29.5 (±12.5) to 21.6 (11.0) and CGI severity of illness score from
4.6 (±0.7) to 3.9 (±0.8) as presented in table 1. A multivariate analysis of variance
including the HDRS and the BDI (scale factor) at baseline and day 25 (time factor)
revealed a significant main effect for the time factor (F=38.5, p<.001). The amount
of symptom reduction did not differ between patient self-ratings (BDI) and
psychiatrist ratings (HDRS) as indicated by the lack of a significant time x scale
interaction.
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Figure 1
N1 evoked potential amplitudes at electrodes Fz, Fcz and Cz. Lines indicate 5 stimulus
intensity levels ranging from 60 dB to 100 dB. The amplitude of the N1 component rises
with higher stimulus intensities.
Intensity slopes of the N1 amplitudes significantly correlated with HDRS reduction
at Fz (r=0.56, p=.025) at Fcz (r=0.55, p=.029) and at Cz (r=0.50, p=.048). No
correlations with HDRS reduction were found for N1 amplitude slopes from C3 and
C4. As illustrated in figure 2, higher intensity slopes of N1 amplitude were
associated with better outcome as indicated by reduction of HDRS scores during
treatment. N1 amplitude intensity slopes were not affected by sex, age, duration
of illness, frequency of episodes of depression, smoking habits (Pearson's
correlation). No correlation emerged for N1 intensity slopes with BDI and CGI
scores. Additionally, no correlations with psychiatric ratings were found for P1,
P1/N1, P2 and N1/P2 amplitude slopes.
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Figure 2
Scatterplot of N1 amplitude slopes at electrode Fz (µV/10dB) correlates with decrease of
HDRS total score within the first three to four weeks of treatment (mean 25 days) with
r=.56, p=.025.
5. Discussion
Our data revealed a significant correlation between intensity slopes of N1
amplitude prior to citalopram-treatment and treatment-response (decrease of
HDRS total score) thus supporting the hypothesis of a strong IDAP being related to
a favorable outcome in SSRI-treatment of major depression. In contrast to earlier
reports, in our study SSRI-treatment was restricted to citalopram [5, 14] and
patients were free of concomitant medication except for three patients treated
with lorazepam in low doses.
In our study, we evaluated a mean period of 25 days. Although this may be
characterized as an initial treatment outcome, our data revealed a significant
improvement in symptoms in the self rated BDI as well as in the psychiatrist rated
HDRS in the course of treatment.
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While several previous studies applied reverse problem solutions like BESA or
LORETA in the evaluation of the N1 auditory intensity dependence [5, 12, 19] other
studies evaluated raw data with regard to N1 [[2, 18], N1/P2 [4, 18] and P2 [14]
amplitude slopes. Here we investigated auditory stimulus intensity with regard to
raw data P1, P1/N1, P2, N1 as well as N1/P2 amplitude slopes. We found
associations of amplitude slopes with treatment outcome only for the N1 but
neither for the P1/N1 nor for the N1/P2 component, probably due to the relatively
small sample of patients.
In summary, our data confirm the hypothesis of a strong intensity dependence of
the auditory evoked potential being associated with a favorable reponse to SSRI
treatment in a group of acutely depressed in-patients treated exclusively with
citalopram. In contrast to previous treatment-studies we found a significant
correlation between pre-treatment intensity dependence of N1 ERP component
and decrease of HDRS scores based on the analysis of raw amplitudes thus
providing a non-invasive, easy applicable method of response-prediction to
pharmacotherapy with citalopram in major depression. Further studies
considering other antidepressants are needed to verify the clinical utility of this
approach in differential indication of serotonergic versus noradrenergic
antidepressants, especially corroborating the hypothesis of a better
responsiveness to Selective Noradrenalin Reuptake Inhibitors (SNRI) in individuals
with major depression showing a low IDAP.
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1. Abstract
The intensity (loudness) dependent amplitude change (IDAP) of auditory evoked
Event Related Potential (ERP) components has been suggested as an indicator of
central serotonergic neurotransmission. In patients with major depression,
associations of high IDAP with favorable SSRI treatment outcome have been
reported. This is the first study to assess the predictive value of the IDAP in SNRI
treatment. We evaluated the pre-treatment intensity dependent change of
auditory evoked P1, N1, P2 as well as P1/N1 and N1/P2 peak to peak amplitudes in
14 in-patients with major depressive episode (DSM IV) in the course of 24 days of
treatment with the SNRI Reboxetine (6 to 12 mg/d). Our data revealed a highly
significant correlation between lower intensity dependent N1 amplitude slopes
prior to Reboxetine treatment and stronger decrease of HDRS total score at Fz
(r=.86, p<.001), Fcz (r=.91, p<.001) and Cz (r=.93, p<.001). This result corroborates
the hypothesis of the IDAP as a differential indicator of serotonergic versus
noradrenergic antidepressant psychopharmacotherapy.
2. Introduction
Predicting treatment response to antidepressant medication has been a challenge
to psychiatric research for decades. The decision either to start
psychopharmacological treatment of major depression with a serotonergic or a
noradrenergic antidepressant has been mainly based on clinical observations, that
led up to now, to a considerable number of initial non-responders. The search for
reliable electrophysiological indicators of serotonergic and noradrenergic
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dysfunction in major depression therapy has therefore recently attracted scientific
interest [6,9,10,12,13,20].
Changes of the N1 and P2 ERP component amplitudes as well as of the P1/N1 and
the N1/P2 peak-to-peak amplitudes in response to different tone intensities have
been suggested as a correlative of central nervous serotonergic activity
[4,9,11,22,25]. The ”intensity dependence” of certain auditory evoked ERP
components means that their amplitude increases with increasing loudness (=
stimulus intensity) of the presented auditory stimuli. A strong loudness dependent
amplitude increase (”strong intensity dependence”) presumably reflects low
serotonergic neurotransmission and vice versa [11]. First investigations on the
intensity dependence of sensory evoked potentials and their relation to psychiatric
disorders by Buchsbaum et al. (1968) and von Knorring et. al. (1978) were based
on the hypothesis of "augmenting/reducing" [4], and recently the same
phenomenon has been described by different terms. The term "IDAP" (intensity
dependence of the cortical auditory evoked potentials) is widely used, especially in
the context of migraine research [19,26] whereas in the context of psychiatric
research, the term "LDAEP" ("loudness dependence of the auditory evoked
potentials") has been suggested [6,9].
Several studies corroborated the concept of the IDAP as an indicator of central
serotonergic neurotransmission. The concentration of 5-hydroxyindoleacetic acid
(main metabolite of serotonin) in cerebrospinal fluid was found to be inversely
correlated with the intensity dependence of sensory evoked potentials [25] and
serotonin agonists reduced the intensity dependence of the N1 amplitude [11,24].
Juckel et al. examined the effects of microinjection of a 5-HT1A agonist and a 5-
HT1A antagonist into the dorsal raphe nucleus (DRN) on auditory evoked
potentials (AEP) recorded epidurally from the primary and secondary auditory
cortex in behaving cats. Injection of a 5-HT1A agonist (8-OH-DPAT), which inhibits
the firing rate of serotonergic DRN neurons, led to a stronger intensity
dependence of AEP from the primary auditory cortex whereas injection of a 5-
HT1A antagonist (Spiperone) reduced AEP intensity dependence when compared
to baseline [11]. In patients under treatment with Serotonin Reuptake Inhibitors
(SSRI) Hegerl et al. (1998) found that high scores in the serotonin syndrome scale
(SSS) were associated with low IDAP and vice versa [9]. Tuchtenhagen et al. (2000)
reported a high intensity dependence of auditory evoked dipole source activity in
abstinent ecstasy (MDMA) users which indicates decreased serotonergic activity
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[23]. Similar results have been decribed by Croft et al. (2001) regarding long-term
MDMA abuse [5]. Strobel et al. (2003) recently found a functional polymorphism in
the promoter region of the serotonin transporter gene (5-HTTLPR) to be
associated with the N1/P2 amplitude intensity dependence [22]: individuals with
the ll genotype exhibited a stronger intensity dependence compared to individuals
with the ls genotype. Conversely, Gallinat et al. (2003) described a weaker IDAP in
individuals homozygous for the l allele compared to heterozygous subjects [7].
Based on these findings the IDAP has been suggested as an psychophysiological
indicator of central serotonergic neurotransmission in depression with special
relevance to treatment-response to SSRI. Paige et al. (1994) found responders to
different serotonergic antidepressants demonstrate significantly higher P2
amplitude slopes (as a function of stimulus intensity) prior to treatment than
nonresponders [18]. Gallinat et al. (2000) reported an association of pre-treatment
N1/P2 amplitude slope with treatment success as indicated by a decrease of
Hamilton scores after 4 weeks in patients treated with various SSRI [6]. Our
research group recently found a better responsiveness to Citalopram treatment in
depressive subjects exhibiting a strong pre-treatment intensity dependence of the
auditory evoked N1 raw amplitude [14].
Considering that all effective antidepressants until now either modify serotonergic,
noradrenergic or both functional systems in brain [17] , in clinical practice non-
responders to SSRI treatment of Major Depression are frequently treated with
selectively or additionally noradrenergic antidepressants. Studies regarding the
predictive value of pre-treatment auditory evoked ERP component amplitude
slopes for treatment outcome with noradrenergic antidepressants are lacking. The
clinical utility of the pre-treatment IDAP in differential prediction of response to
serotonergic versus noradrenergic antidepressants is basically influenced by the
question, whether the IDAP is not only related to SSRI response but to
responsiveness to noradrenergic antidepressants as well. Therefore, the aim of our
study was to assess the predictive value of pre-treatment intensity dependent
auditory evoked ERP component (P1, N1, P2, P1/N1, N1/P2) amplitude slopes in a
sample of patients with major depression, who were exclusively treated with the
Selective Noradrenalin Reuptake Inhibitor (NARI) Reboxetine.
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3. Method
Subjects: Fourteen in-patients with major depressive episode (DSM-IV: 296.2,
296.3, 296.5; APA 1994), who were admitted consecutively to the Department of
Psychiatry and Psychotherapy of the University of Duisburg-Essen and considered
candidates for an antidepressant medication with Reboxetine, were included in
the study. Patient characteristics are given in Table 1.
Table 1
Subject characteristics
n 14
Age 45.2 (±11.8)
Gender (m/f) 4/10
Education (y) 12.9 (±2.0)
Nicotine (n; mg/d) 6; 14.9 (±20.4)
Episodes of depression (n) 2.7(±2.4)
Duration (y) 10.0 (±8.6)
Dose of citalopram (Day 25) 8.4 (±1.4)
CGI (Baseline/25) 4.6 (±1.4)/3.4 (±1.1)
HDRS (Baseline) 24.1 (±3.7)/11.6 (±7.2)
BDI (Baseline) 23.7 (±10.6)/15.4 (10.7)
Rating scales and procedure: Clinical symptoms of major depression were assessed
by means of psychiatric rating scales: Clinical Global Impression (CGI) [16],
Hamilton Rating Scale for Depression (HDRS, 21 items) [8] and Beck Depression
Inventory (BDI) [2]. Clinical ratings were performed by a senior psychiatrist who
had no information on patients' ERP data. The total score of HDRS had to be at
least 20. Patients gave their written informed consent prior to their inclusion in
the study. The study was approved by the local Ethics Committee. ERP data were
recorded one day before beginning pharmacological treatment with Reboxetine
(baseline). The CGI, HDRS and BDI scores were obtained at the day of ERP
recordings and again after three to four weeks of treatment (mean: 24 days). Pre-
treatment antidepressants (six patients) were stopped at least two days before the
ERP recording. Central neurological disorders, abuse of illicit drugs and alcohol
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dependence were excluded, as was pre-treatment with electroconvulsive therapy.
Following the ERP-recording, patients were treated with Reboxetine (range: 6 to
12 mg) for 24 (21 – 28) days. Concomitant medication with antipsychotics, mood
stabilizers or additional antidepressants was not allowed. Concomittant
benzodiazepine treatment (n=2) was restricted to a maximum dose of 1.5mg
Lorazepam per day. Lorazepam was not given 12 hours before ERP-recording.
Electrophysiological assessment and data analysis: ERP data were recorded in a
sound-attenuated and electrically shielded room. Subjects were seated in a
comfortable armchair. Auditory stimulation was done in two runs of 500 stimuli
each with an interstimulus-intervall randomized between 500 ms and 900 ms.
Auditory stimuli of 1000 Hz, with 80 ms duration (10 ms rise / fall) were presented
at five intensities of 60, 70, 80, 90 and 100 dB sound pressure level via TDH-39p
headphones (Telephonics Inc.) in randomized order. The auditory threshold with
respect to 1000 Hz tones was below 30 dB as measured by an audiometer.
Stimulus presentation was generated by Neuroscan Stim 3.3 Software. Evoked
potentials were recorded from 27 scalp electrodes (extended international 10-20
system) with linked earlobes as reference using a 32-channel EEG amplifier
(Neuroscan Inc.). A vertical and horizontal electro-oculogram (EOG) was recorded
for offline artifact removal [21]. ERP data were recorded with a sampling rate of
500 Hz in the frequency range of 0.1 to 100 Hz. ERP data were filtered offline with
a 0.1 Hz to 30 Hz bandpass filter (Neuroscan Edit 4.1). EEG data were segmented
into periods of 600 ms starting 200 ms prior to stimulus onset. The 200 ms
baseline was chosen because of slightly more stable results when compared to
more traditional 100 ms baseline [1]. Segments with artifacts exceeding +/- 50 µV
were rejected from further analysis. ERP averages were computed for each
stimulus intensity level. Mean sweep numbers ranged between 114.5 and 137.5
sweeps for intensities between 60 dB up to 100 dB. Amplitudes of the N100 and
the P200 components were computed from electrode Fz, Fcz, Cz, C3 and C4.
Intensity slopes (amplitude slope function derived by linear regression across
stimulus intensity levels) were computed for the P1, N1, P2 amplitudes and the
P1/N1 and N1/P2 peak to peak amplitudes. All statistical analyses were performed
using SPSS 11.5. All used variables showed a normal distribution (Kolmogorov-
Smirnov-Test) and were therefore computed as Pearson’s correlation.
Prediction of reboxetine response
-62-
4. Results
Rating scales: Psychiatric rating scores significantly improved from baseline to
follow-up after 24 days of treatment: HDRS total score decreased from 24.1 (±3.7)
to 11.6 (±7.2), BDI total score from 23.7 (±10.6) to 15.4 (±10.7) and CGI severity of
illness score from 4.9 (±0.5) to 3.4 (±1.1) as presented in Table 1. A multivariate
analysis of variance including the HDRS and the BDI (scale factor) at baseline and
day 24 (time factor) revealed a significant main effect for the time factor (F=44.8,
p<.001). The amount of symptom reduction did not differ between patient self-
ratings (BDI) and psychiatrist ratings (HDRS) as indicated by the lack of a significant
time x scale interaction.
ERP data: Mean amplitudes of the N1 at electrode Fz increased from –2.93 µV
(±2.17) at 60 dB to –5.70 µV (±3.40) at 100 dB; at electrode Fcz from –3.20 µV
(±2.17) at 60 dB to –5.9 µV (±3.14) at 100 dB; at electrode Cz from –3.15 µV (±2.0)
at 60 dB up to –5.64 µV (±2.63) at 100 dB; at C3 from –2.96 µV (2.0) to –5.57 µV
(±3.23), and at C4 from –2.96 µV (±1.64) to –5.25 µV (±2.88). N1 intensity slopes
(µV / 10 dB) at Fz, Fcz, Cz, C3 and C4 were 0.64 (±0.53), 0.65 (0.45), 0.61 (±0.37),
0.64 (±0.47) and 0.57 (±0.47) respectively. The P1/N1 intensity slopes were 0.64
(±0.47), 0.68 (±0.47), 0.69 (±0.45), 0.69 (±0.50) and 0.66 (±0.58) respectively and
the N1/P2 intensity slopes were 0.65 (±0.64), 0.83 (±0.58), 0.89 (±0.55),
0.65(±0.73) and 0.59 (±0.68) respectively. Group averages for electrodes Fz, Fcz
and Cz are shown in Figure 1.
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Figure 1
N1 evoked potential amplitudes at electrodes Fz, Fcz and Cz. Lines indicate 5
stimulus intensity levels ranging from 60 dB to 100 dB. The amplitude of the N1
component rises with higher stimulus intensities.
Correlations with treatment response: We found highly significant correlations of
low intensity slopes of the N1 and high HDRS reduction at Fz (r=.86, p<.001) at Fcz
(r=.91, p<.001), at Cz (r=.93, p<.001), C3 (r=.81, p<.001) and C4 (r=.75, p<.001). As
illustrated in Figure 2, higher intensity slopes of N1 amplitude were associated
with better outcome as indicated by reduction of HDRS scores during treatment.
N1 amplitude intensity slopes were not affected by sex, age, duration of illness,
frequency of depression episodes or smoking habits (Pearson's correlation).
Significant correlations ((Pearson's) with HDRS reduction were found for P1/N1
peak to peak amplitude slopes at Fz (r=.68, p<.001) at Fcz (r=.63, p=.015), at Cz
(r=.56, p=.038) and C3 (r=.63, p=.017) and N1/P2 amplitude slopes at Fz (r=.70,
p<.001) and at Fcz (r=.56, p=.036). No correlations emerged from the assessment
of P2 amplitude slopes or from ERP intensity slopes and BDI or CGI scores.
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Figure 2
Scatterplot of N1 amplitude slopes at electrode Cz (µV/10dB) correlates with
decrease of HDRS total score within the first three to four weeks of treatment
(mean 24 days) with r=.93, p<.001.
Split-half reliabilities for the N1 amplitude at Fz, Fcz and Cz were calculated
separately for each level of intensity. Correlation coefficients ranged between
0.879 and 0.919 (p <0.001) at Fz, 0.89 and 0.93 (p <0.001) at Fcz and 0.90 and
0.93 (p <0.001) at Cz, which indicates a good temporal stability across the two
runs.
5. Discussion
Our data revealed a significant correlation between low intensity slopes of N1
amplitude prior to Reboxetine treatment and favorable treatment response
(decrease of HDRS total score) thus supporting the hypothesis of a low IDAP being
related to a favorable outcome in SNRI-treatment of major depression.
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In contrast to earlier reports [6,18] patients were free of concomitant medication
with the exception of two patients treated with low doses of Lorazepam. In these
two cases the daily doses of Lorazepam were 0, 5 mg since 2 days and 1 day
respectively and the last dose was given 24 h before ERP recording in both cases.
Due to organizational reasons the final psychiatric ratings were done after a
minimum of 21 and a maximum of 28 days. The date of the final ratings for each
patient was chosen independently from patients’ psychiatric state. We evaluated a
mean period of 24 days in our study. Although this might be characterized as an
initial treatment outcome, our data revealed a significant mean improvement of
symptoms in the self-rated BDI as well as in the psychiatrist rated HDRS during the
course of treatment.
While several previous studies applied reverse problem solutions like BESA or
LORETA in the evaluation of the N1/P2 auditory intensity dependence [6,12,15,23]
other studies evaluated raw data with regard to N1 [3,14,22], N1/P2 [5,14,22] and
P2 [14,18] amplitude slopes. Here we investigated auditory stimulus intensity with
regard to raw data P1, P1/N1, P2, N1 and N1/P2 amplitude slopes. In comparison
to several other authors we applied a relatively short interstimulus interval (ISI).
The ISI varied randomly around 700 ms +/- 200 ms in order to avoid the theoretical
problem of a faster habituation to tone intensity differences. Speculatively, our
clear results from the analyses of ERP components’ raw amplitudes are due to the
short but varying ISI.
We found highly significant associations of ERP amplitude slopes with treatment
outcome predominantly for the N1 amplitude and to a lesser extent for P1/N1 and
the N1/P2 component as well, but not for P2 component. Paige et al. (1994) found
a significant correlation of P2 amplitude intensity dependence with SSRI treatment
outcome [15] and Beauducel et al. (2000) suggested that the P2 amplitude slopes
reflect stimulus intensity changes more precisely than other ERP component
slopes [1]. In contrast, in our data the intensity dependence of P2 amplitudes was
not significantly associated with NARI treatment outcome. This negative result
may have been due to our relatively small sample or to methodological
differences, i.e. the short ISI in our paradigm. However, considering high split-half
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coefficients indicating high internal consistency and intensity slopes compatible
with previously reported studies, a lack of data quality seems unlikely.
Although the amount of symptom reduction did not differ between BDI and HDRS,
we could not find a significant correlation between these rating scales in our
sample, which indicates an inconsistency between patients’ and psychiatrists’
ratings. That is probably the reason for the missing correlation between decrease
of BDI and IDAP in our study.
Our data confirm the hypothesis of a low intensity dependence of the auditory
evoked potential being associated with a favorable response to SNRI treatment in
a group of acutely depressed in-patients treated exclusively with Reboxetine. In
contrast to previous treatment-studies we found a significant correlation between
pre-treatment intensity dependence of ERP component amplitude slopes and
decrease of HDRS scores based on the analysis of raw amplitudes. As a low IDAP is
associated with a favorable response to SNRI treatment and a high IDAP with a
favorable response to SSRI treatment in major depression, this approach may
provide an easily applicable method for clinicians in the initial differential
indication of serotonergic versus noradrenergic antidepressants.
Nevertheless, further studies are needed in order to replicate these results in a
larger sample of patients comparing SSRI and SNRI treatment in a randomized and
double-blind setting. Future studies may investigate the impact of the
norepinephrine transporter gene polymorphism on the IDAP in a large sample of
healthy subjects in order to clarify connections between noradrenergic function
and ERP measures of auditory intensity processing [27] as demonstrated in
studies, which assessed the 5-HTTLPR polymorphism [7,22].
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STIMULUS INTENSITY DEPENDENT ERP COMPONENTS IN THE
PHARMACOTHERAPY OF MAJOR DEPRESSIVE DISORDER
CHAPTER 4
THE INTENSITY DEPENDENCE OF
AUDITORY ERP COMPONENTS IN
UNMEDICATED PATIENTS WITH
MAJOR DEPRESSION AND HEALTHY
CONTROLS. AN ANALYSIS OF GROUP
DIFFERENCES.
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1. Abstract
The intensity dependent amplitude change (IDAP) of auditory evoked Event
Related Potential (ERP) components has been found to correlate with the level of
central serotonergic neurotransmission and to be associated with response to
certain antidepressants. However, it is currently unknown whether there is a
general abnormality of the IDAP in patients with major depression. Therefore, the
purpose of the present study was to compare the IDAP in unmedicated depressed
patients with that of healthy control subjects. We report the results of a study
evaluating the change of auditory evoked P1, N1, P2 as well as P1/N1 and N1/P2
peak to peak amplitudes in 34 in-patients with major depressive episode prior to
antidepressant treatment, and 44 healthy control subjects. Clinical symptoms of
depression were assessed by means of standardized psychiatric rating scales (CGI,
HDRS, HAMA and BDI). In multivariate analyses of variance we found no group
differences in the intensity dependent increase neither of the P1, N1, and P2 nor
of the P1/N1 and N1/P2 peak to peak amplitudes between patients and controls.
Our data revealed no general abnormality of the IDAP in patients with major
depression in comparison to healthy control subjects. This result suggests that
specific alterations of the IDAP are not to be expected in major depression in
general, these may be confined to subgroups of depressed patients.
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2. Introduction
Major concepts on the pathophysiology of depression comprise alterations in
serotonergic and noradrenergic systems in brain (Owens, 2004) and changes in the
hypothalamic-pituitary-adrenal axis (Riedel et al., 2002). In particular, the search
for reliable indicators of central serotonergic and noradrenergic dysfunction in
major depression has recently attracted scientific interest. Beside genetic
approaches (Yoshida et al., 2004) several authors used auditory event related
potential (ERP) components in the investigation of serotonergic dysregulation in
patients with major depression (review in: Hegerl et al., 2001).
Cortical responses to auditory stimulation derived from EEG in the form of ERPs
consist of three typical components: An electrically positive P1 component at
about 50 ms following stimulus onset, a negative N1 component at 100 ms and a
positive P2 component at about 200 ms. Increases in auditory stimulus intensities
are reflected by increases in ERP amplitudes. Typically, several stimulus intensities
are used to elicit amplitude changes which can be transformed into slope values
which give the amplitude change in µV per 10/dB (Beauducel et al., 2000).
Changes of the N1 and P2 ERP component amplitudes as well as of the P1/N1 and
the N1/P2 peak-to-peak amplitudes in response to different tone intensities have
been identified as a correlative of central nervous serotonergic activity
(Buchsbaum and Silverman, 1968; Hegerl et al., 1998; Juckel et al., 1999; Strobel et
al., 2003; von Knorring and Perris, 1981). A high loudness dependent amplitude
increase (“high intensity dependence”, “high IDAP”) presumably reflects low
serotonergic neurotransmission and vice versa (Juckel et al., 1999).
Buchsbaum et al. (1968) et al. described the phenomenon of
augmenting/reducing, which is considered to reflect individual differences in the
modulation of sensory input (Buchsbaum and Silverman, 1968). Individuals who
showed an increase of ERP amplitudes with increasing stimulus intensity were
classified as augmenters and individuals who showed a decrease of ERP
amplitudes with increasing stimulus intensity as reducers. First investigations on
the intensity dependence of sensory evoked potentials and their relation to
psychiatric disorders by Zuckerman et a. (1974) focused on the relation between
stimulus intensity dependence and personality factors like impulsiveness,
aggressiveness and sensation seeking behaviour (Zuckerman et al., 1974).
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Based on theories about the role of serotonin in the pathophysiology of migraine
the stimulus intensity dependence of ERP components has been investigated in
the context of migraine research, where the term "IDAP" (intensity dependence of
the cortical auditory evoked potentials) is widely used (Proietti-Cecchini et al.,
1997a; Wang et al., 1996). Within psychiatric research Hegerl et al. introduced the
term "LDAEP" ("loudness dependence of the auditory evoked potentials") (Gallinat
et al., 2000; Hegerl et al., 1998), whereas other authors used the term “IDAP” in
psychological and psychiatric investigations as well (Hensch et al., 2006). In the
description of our investigations we decided to use the “traditional” term of IDAP.
Several studies corroborated the concept of the IDAP as an indicator of central
serotonergic neurotransmission. Juckel et al. reported differential effects of
microinjection of a 5-HT
1A
agonist and a 5-HT
1A
antagonist into the dorsal raphe
nucleus (DRN) on the intensity dependence of auditory evoked potentials (AEP)
recorded epidurally from the primary and secondary auditory cortex in behaving
cats. (Juckel et al., 1999). Strobel et al. (2003) found a functional polymorphism in
the promoter region of the serotonin transporter gene (5-HTTLPR) to be
associated with the N1/P2 amplitude intensity dependence. This result has been
recently replicated by Hensch et al. (2006).
The role of the IDAP has been studied in several fields of psychiatric research:
Tuchtenhagen et al. (2000) reported a high intensity dependence of auditory
evoked dipole source activity in abstinent ecstasy (MDMA) users which indicates
decreased serotonergic activity (Tuchtenhagen et al., 2000). Similar results have
been decribed by Croft et al. (2001) regarding long-term MDMA abuse. A high
IDAP has been described to correlate with aspects of impulsiveness in 15 female
patients suffering from borderline personality disorder (Norra et al., 2003). Juckel
et al. found the IDAP of the primary auditory cortex derived from dipole source
analysis in 25 inpatients with schizophrenia to be significantly lower compared to
25 healthy controls. After treatment with the 5-HT(2) antagonistic antipsychotics
Clozapine and Olanzapine, the IDAP tended to be increased, indicating
normalization of serotonergic function in the patients with schizophrenia under
antipsychotic treatment (Juckel et al., 2003). Applying dipole source analysis
Senkowski et al. described a significantly lower IDAP derived from bilateral
tangential dipoles in 31 medication-free patients with General Anxiety Disorder in
comparison to 31 matched control subjects (Senkowski et al., 2003). In patients
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under treatment with Serotonin Reuptake Inhibitors (SSRI) Hegerl et al. (1998)
found that high scores in the serotonin syndrome scale (SSS) were associated with
low IDAP and vice versa (Hegerl et al., 1998).
Based on such preclinical and clinical studies the IDAP has been suggested as a
psychophysiological indicator of central serotonergic neurotransmission in
depression with special relevance to treatment-response to SSRI. This concept has
been corroborated in several studies applying various antidepressants (Paige et al.,
1994; Gallinat et al., 2000; Lee et al., 2005; Linka et al., 2004; Linka et al., 2005).
Although preclinical and clinical studies indicate that the IDAP can be useful in the
evaluation of serotonergic dysfunction, it is still unknown, if the IDAP in
unmedicated depressed patients basically differs from that of healthy control
individuals. However, the IDAP in major depression has been compared to control
subjects only in the context of a treatment response study by Gallinat et al. 2000.
In this study nonresponders but not responders to SSRI showed a reduced
loudness dependent increase of the tangential dipole of the N1/P2 complex
(dipole source analysis). While these data indicate at least some differences
between control subjects and patients with major depression, it remains
unknown, whether patients with major depression show a general alteration in
the IDAP.
In summary, there is accumulating evidence, that the IDAP is an indirect indicator
of central serotonergic neurotransmission in major depression and other
psychiatric disorders. As central nervous serotonergic dysfunction is suggested to
be one of the major pathophysiological factors in depression, healthy controls and
patients should differ with regard to this indicator. As most studies suggest that a
high IDAP is associated with superior responsiveness to SSRI-treatment in
depression, this study aims to investigate the hypothesis that individuals suffering
from major depression exhibit a higher IDAP compared to healthy control subjects.
3. Method
3.1 Subjects
Thirty-four in-patients with major depressive episode (DSM-IV: 296.2, 296.3,
296.5; APA 1994), who were admitted consecutively to the Department of
Psychiatry and Psychotherapy of the University of Duisburg-Essen and 44 matched
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healthy control subjects, were included for participation in the study. Patients and
controls gave their written informed consent prior to their inclusion in the study.
The study was approved by the local ethics committee. Controls were recruited via
advertisements in local community centers and stores. Control subjects
recruitement was done with regard to the matching criteria age, gender and
education of the patient sample. Patients and controls did not differ with regard to
age and gender (table 1).
3.2 Rating scales and procedure
Clinical symptoms of major depression were assessed by means of psychiatric
rating scales: Clinical Global Impression (CGI) ((NIMH), 1976), Hamilton Rating
Scale for Depression (HDRS, 21 items, range of scores: 0 - 63) (Hamilton, 1960),
Beck Depression Inventory (BDI, 21 items, range of scores: 0 - 63) (Beck et al.,
1961), Hamilton Anxiety Scale (HAMA, 14 items, range of scores: 0 – 56)
(Hamilton, 1976)and State-Trait-Anxiety Inventory (STAI range of scores: 40, 40 –
160) (Spielberger, 1970).
Table 1
Subject characteristics
Patients with
Major Depression
means (sd)
Healthy Control
Subjects
means (sd)
Age
Gender (m/f)
Education (y)
Nicotine (n; mg/d)
Episodes of depression (n)
Duration of illness (y)
CGI total score
HDRS total score
HAMA total score
BDI total score
STAI total score
41.4 (± 12.6)
11 / 23
10.6 (± 1.6)
18; 19.6 (± 17.4)
1.9 (± 1.9)
8.9 (± 7.6)
4.7 (± 1.0)
24.5 (± 4.1)
8.5 (± 7.6)
27.8 (±10.7)
58.7 (±13.3)
39.2 (± 10.4)
16 / 28
13.9 (± 2.6)
22; 14.11 (± 9.2)
-
-
-
-
-
3.1 (±3.1)
33.3 (±8.8)
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Clinical ratings were performed by a experienced senior psychiatrist who was blind
to patients' ERP data. The BDI and STAI self rating scales were completed by all
subjects in order to exclude individuals with clinically relevant anxiety and
depression within the controlgroup. The total score of HDRS in patients had to be
20 at least. The CGI, HDRS and BDI scores were obtained at the day of ERP
recording. Pre-treatment antidepressants were stopped at least two days before
ERP recording. Patients with central neurological disorders, abuse of illicit drugs
and alcohol dependence were excluded, as was pre-treatment with
electroconvulsive therapy. Concomitant medication with antipsychotics, mood
stabilizers or additional antidepressants was not permitted and patients receiving
antidepressants within three months before hospitalisation were excluded from
the study. Concomittant benzodiazepine treatment (n=2) was restricted to a
maximum dose of 1.5 mg Lorazepam per day. Lorazepam was not given 12 hours
before ERP-recording.
3.3 Electrophysiological assessment and data analysis
EEG-recording took place in a sound-attenuated and electrically shielded room.
Subjects were seated in a comfortable chair. Auditory stimulation consisted of two
runs of 500 stimuli each with the interstimulus-intervall being randomized
between 500 and 900 ms. Tones of 1000 Hz and 80 ms duration (10 ms rise and
fall times) were presented with five intensities namely 60, 70, 80, 90 and 100 dB
sound pressure level via TDH-39p headphones (Telephonics Inc.). The stimulus
intensities where presented in randomized order. The auditory threshold with
respect to 1000 Hz tones was below 30 dB as measured by an audiometer.
Stimulus presentation was generated by Neuroscan Stim 3.3 Software. Evoked
potentials were recorded from 27 scalp electrodes (extended international 10-20
system) with linked earlobes as reference using a 32-channel EEG amplifier
(Neuroscan Inc.). The vertical and horizontal electro-oculogram (EOG) was
recorded for offline artifact removal (Semlitsch et al., 1986). EEG data were
recorded with a sampling rate of 500 Hz in the frequency range of 0.1 to 100 Hz
and filtered offline with a 0.1 Hz to 30 Hz bandpass filter (Neuroscan Edit 4.2). ERP
sweeps extended over 600 ms starting 100 ms prior to stimulus onset. Sweeps
with artifacts exceeding +/- 50 µV were rejected from further analysis. ERP
averages were computed separately for each stimulus intensity level. Mean
number of sweeps ranged from 114.5 to 137.5. Amplitudes of the N100 and the
P200 components were computed from electrodes Fz, Fcz, Cz, C3 and C4.
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Amplitude slopes (amplitude slope function derived by linear regression across
stimulus intensity levels) were computed for the P1, N1, P2 amplitudes and the
P1/N1 and N1/P2 peak to peak amplitudes.
3.4. Statistical analysis
ERP Amplitude data of the P1, N1, P2 amplitudes and the P1/N1 and N1/P2 peak
to peak amplitudes were analysed in separate multivariate analyses of variance
with stimulus intensities (60, 70, 80, 90, 100 dB) and electrodes (Fz, Fcz, Cz, C3, C4)
as within factors and group (patients / control) as between factor. Reports on
results are restricted to effects involving the group factor and group x intensity
interactions. Group effects indicate differences in mean amplitudes between
patients and controls and group x intensity interactions indicate differences in the
auditory intensity dependent amplitude slopes between patients and control
subjects. Effects of gender, and smoking habit on amplitude slopes were assessed
with Chi² tests and the effects of age, education and the amount of nicotine
consumption among smoking subjects were assessed with analysis of variance.
The impact of duration of illness and the frequency of depression episodes on
evoked potentials were assessed with Pearson correlations.
4. Results
4.1 Rating scales
Patients and controls did not differ significantly with regard to age, gender,
smoking status and the amount of nicotine intake per day in smoking subjects.
Patients spent a lower time in school education than control subjects (p = .015).
Results of clinical ratings are shown in table 1.
4.2 ERP data
N1 amplitude slopes were not affected by sex, age, education, duration of illness,
frequency of depression episodes or smoking habits. Results of ERP-data analysis
are presented in table 2. Group averages in patients and controls for electrode Cz
are shown in figure 1.
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Figure 1
Group averages of the N1 component at electrode CZ in patients with major
depression and control subjects. Lines indicate five stimulus intensity levels
ranging from 60 to 100 dB. The amplitude of the N1 component increases with
higher stimulus intensities.
Five multivariate analyses of variance including group (between factor: patients,
controls) and stimulus intensities (within factor: 60, 70, 80, 90, 100 dB) were
computed for P1, N1, P2 amplitudes and the P1/N1 and N1/P2 peak to peak
amplitudes. We found no significant effects for the group factor or for group x
intensity interactions at the Bonferoni corrected level of p<.01 (p=.05 / 5 analyses).
Figure 2 shows mean amplitudes over the five auditory intensity levels for patients
with major depression and healthy control subjects at electrode Cz.
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Figure 1
N1 group means of the amplitudes at electrode Cz evoked by stimulus intensities 60 to 100
dB. Compared to patients, controls showed a slightly higher intensity dependent amplitude
increase at Cz, in an overall analysis of electrodes Fz, Fcz, Cz, C3, C4 we found no significant
group differences.
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Table 2
ERP Data: N1 amplitudes and N1, P1/N1, N1/P2 amplitude slopes
Major Depression
mean (sd)
Healthy
Control Subjects
mean (sd)
N1 amplitude 60 dB/100 dB
(µV) *
Fz
Fcz
Cz
C3
C4
–3.25 (±2.1) / –5.80 (±3.6)
–3.29 (±2.1) / –5.92 (±3.1)
–3.10 (±1.9) / –5.57 (±2.8)
–2.90 (±1.9) / –5.18 (±2.7)
–2.87 (±1.7) / –4.92 (±2.6)
–3.69 (±1.8) / –6.91 (±2.3)
–3.67 (±1.8) / –7.18 (±2.6)
–3.41 (±1.5) / –7.00 (±2.1)
–3.10 (±1.4) / –6.19 (±1.9)
–2.96 (±1.3) / –5.90 (±1.8)
N1 amplitude slope (µV / 10
dB)#
Fz
Cz
Fcz
C3
C4
0.62 (±0.5)
0.66 (±0.5)
0.62 (±0.4)
0.56 (±0.4)
0.52 (±0.4)
0.77 (±0.5)
0.84 (±0.5)
0.84 (±0.4)
0.71 (±0.3)
0.69 (±0.3)
P1/N1 amplitude slope (µV/10
dB)#
Fz
Fcz
Cz
C3
C4
0.69 (±0.5)
0.77 (±0.5)
0.76 (±0.5)
0.63 (±0.5)
0.71 (±0.5)
0.86 (±0.5)
1.01 (±0.5)
1.03 (±0.4)
0.86 (±0.4)
0.70 (±0.4)
N1/P2 amplitude slope (µV/10 dB
Fz
Cz
Fcz
C3
C4
0.64 (±0.6)
0.80 (±0.6)
0.85 (±0.6)
0.67 (±0.5)
0.63 (±0.5)
0.84 (±0.6)
1.10 (±0.6)
1.16 (±0.6)
0.85 (±0.4)
0.93 (±0.5)
* Evoked response (ERP) amplitude data are given for the lowest (60 dB) and the highest
(100 dB) auditory stimulus intensities at electrode positions Fz, Cz, Fcz, C3 and C4 in µV.
#
Amplitude slopes give the absolute value of the mean increase in ERP amplitudes within
the five (60, 70, 80, 90 and 100 dB) stimulus intensities in µV per 10 dB.
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5. Discussion
This is the first report to compare a large sample of unmedicated patients with
major depression with a group of healthy control subjects with regard to general
abnormalities in the IDAP. We conducted analyses over five commonly used
methods in the calculation of amplitudes (P1/baseline, N1/baseline, P2/baseline,
P1/N1, N1/P2).
Although, compared to patients, controls showed a slightly higher intensity
dependent amplitude increase at Cz (see figure 2), in an overall analysis of
electrodes Fz, Fcz, Cz, C3, C4 we found no significant group differences. Given the
sample size and compared to the highly significant predictive power of the IDAP
with regard to treatment outcome (Gallinat et al., 2000; Lee et al., 2005; Linka et
al., 2004; Linka et al., 2005) the IDAP baseline, differences between patients and
controls at Cz were small (Figure 2) and after adjustment for multiple testing
(Bonferoni) turned out to be non-significant.
While several previous studies applied reverse problem solutions like BESA (dipole
source analysis) or LORETA in the evaluation of the N1/P2 auditory intensity
dependence (Gallinat et al., 2000; Mulert et al., 2002; Tuchtenhagen et al., 2000)
other studies evaluated raw data with regard to N1 [(Brocke et al., 2000; Strobel et
al., 2003), N1/P2 (Croft et al., 2001; Strobel et al., 2003) and P2 (Paige et al.,
1994) amplitude slopes. However, there is no unambiguous evidence that reverse
methods of ERP analysis are superior to the evaluation of raw amplitudes. In line
with earlier studies in this field, here we assessed auditory stimulus intensity with
regard to raw data P1, P1/N1, P2, N1 and N1/P2 amplitude slopes.
The intensity dependent amplitude slopes of the subjects in our study can be
compared to those obtained in previous studies using similar procedures and
measures. While our inter-stimulus interval between 500 ms and 900 ms is at the
lower end of what has been used by other groups, stimulus intensities, electrode
positions and stimulus intensity slope calculation are in keeping with previously
employed methods (Beauducel et al., 2000). The resulting N1/P2 amplitude slopes
in our study are in line with results reported by Sandor et al. (Sandor et al., 1999).
They are however lower than those reported by Croft et al. (Croft et al., 2001) and
higher than those in a study by Cecchini et al. (Proietti-Cecchini et al., 1997b).
Therefore we may conclude, that results from our experimental setup are
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comparable to previously reported results assessing healthy subjects with similar
methods and that the lack of significant differences in auditory evoked potentials
between patients with major depression and matched healthy control subjects is
unlikely to be related to methodological factors.
The lack of a difference between patients and controls with regard to the IDAP in
our study seems to be contradictory to those studies, which support the
significance of the IDAP as a clinically relevant indicator of the central nervous
serotonergic dysfunction in depressive disorders.
Paige et al. (1994) found responders to different serotonergic antidepressants
demonstrate significantly higher P2 amplitude slopes (as a function of stimulus
intensity) prior to treatment than non-responders (Paige et al., 1994). Our
research group recently reported a superior responsiveness to Citalopram
treatment in depressed patients exhibiting a high pre-treatment intensity
dependence of the auditory evoked N1 raw amplitude (Linka et al., 2004), and to
Reboxetine treatment in depressed patients exhibiting low pre-treatment intensity
dependence (Linka et al., 2005). These studies support the clinically relevant
sensitivity of the IDAP as an indicator of central nervous serotonergic dysfunction.
In a study by Gallinat et al. (2000) patients with a high pre-treatment IDAP (based
on dipole source analysis; bilateral tangential dipoles) showed significantly lower
HDRS scores after 4 weeks of treatment with SSRI than patients with a low IDAP
(Gallinat et al., 2000). However, in this study authors failed to show changes in the
IDAP after four weeks of SSRI treatment in a subsample of 19 patients between
the first and the second assessment. Although Gallinat et al. in line with our results
did not find a general abnormality of the IDAP when comparing the whole sample
of depressed patients with the healthy control group, their data revealed a lower
mean IDAP within the group of depressed non-responders to SSRI treatment
compared to controls.
In our study variances of the IDAP were only slightly larger in patients than in
controls (table 2). It can be hypothized that a subgroup of controls as well as
patients shows some kind of dysregulation of the serotonergic system. Considering
the results from MDMA-users (Croft et al., 2001; Tuchtenhagen et al., 2000), the
findings in schizophrenia [13], borderline personality disorder [20] an general
anxiety disorder [28] and the association between IDAP and the Serotonin
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Syndrom Scale (Hegerl et al., 1998) the IDAP seems to reflect the sensitivity of the
central serotonergic system. The results of our study do not necessarily contradict
the assumed role of the IDAP as an indicator a central nervous serotonergic
sensitivity in major depression and other psychiatric disorders. The phenomenon,
that only a subgroup of depressed individuals shows associations with a biological
factor, assumed to reflect serotonergic sensitivity, is known from genetic
approaches. This might be exemplified by a study by Willeit et al. (2003) over the
role of a polymorphism in the promoter region of the serotonin transporter (5-
HTTLPR) in seasonal affective disorder. While Willeit found no difference between
patients and controls for genotype distribution and s-allele frequency, genotype
distribution and allele frequencies were associated with DSM-IV depression
subtypes. Melancholic depression was associated with the 5-HTTLPR long (l) allele
and atypical depression with the 5-HTTLPR s-allele (Willeit et al., 2003). Similarly,
the lack of a difference between patients and controls with regard to the IDAP in
our study might be due to the independence of this factor from the clinically
observed, general depressive state and from major depression itself. Thus
alterations of the IDAP in major depression may be expected in a subgroup of
depressed patients only, which is affected by a potentially higher degree of
dysfunction in the central nervous serotonergic neurotransmission.
Our study presents normal values for the IDAP derived from 44 healthy control
subjects and reveals that there is no general abnormality of the IDAP in major
depression. These results should be helpful in further studies combining ERP,
genetic approaches (NET- and 5HT polymorphisms) in a double blind, randomized
setting with different classes of antidepressants (SSRI, NARI, SNRI). Furthermore it
could be of interest to evaluate if there is a link between abnormalities in the IDAP
and subgroups of patients with depressive disorders and whether these can be
identified by certain patterns of clinical symptomatology of depression.
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STIMULUS INTENSITY DEPENDENT ERP COMPONENTS IN THE
PHARMACOTHERAPY OF MAJOR DEPRESSIVE DISORDER
CHAPTER 5
CLINICAL SYMPTOMS OF MAJOR
DEPRESSION ARE ASSOCIATED WITH
THE INTENSITY DEPENDENCE OF
AUDITORY ERP COMPONENTS.
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1. Abstract
The intensity (loudness) dependent amplitude change (IDAP) of auditory Event
Related Potential (ERP) has been shown to be associated with the outcome of SSRI
treatment in major depression. The purpose of the present study is to evaluate
associations between clinical symptoms of major depression and the IDAP as an
indirect indicator of cortical serotonergic function. We assessed 40 in-patients
suffering from a major depressive episode (DSM-IV) prior to antidepressant
treatment. Psychometric characteristics of depression were assessed by means of
psychiatric rating scales (CGI, HDRS, HAMA, STAI and BDI) and evaluated for
associations with auditory evoked P1, N1, P2 as well as P1/N1 and N1/P2 peak to
peak amplitude slopes. Our data revealed a positive correlation of the intensity
dependent N1 amplitude slope with the degree of certain somatic symptoms of
depression: loss of appetite and weight, insomnia, and sexual dysfunction. The
results of our study might contribute to a more specific clinical basis in the
differential indication of serotonergic versus noradrenergic antidepressants.
2. Introduction
The increasing number of available antidepressants leads to a growing interest in
the prediction of treatment reponse to different classes of antidepressants. The
traditional clinical way of deciding, whether to use a serotonergic or noradrenergic
antidepressant in the pharmacotherapy of depression, is often based on more or
less clearly identifiable clinical subtypes of depression, for instance “anxious
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depression” (Fava et al., 2000) or “melancholic depression” (Perry, 1996) and thus
leads to a considerable number of initial non-responders. Therefore it seems to be
of clinical interest to evaluate if certain symptoms of depression might be
associated with an altered central serotonergic sensitivity.
In human electrophysiology research the search for reliable indicators of central
serotonergic dysfunction in major depression has particularly attracted scientific
interest in recent years. Considering that main concepts on the pathophysiology of
depression comprise alterations in the central serotonergic neurotransmission and
sensitivity (Owens, 2004), several authors used auditory Event Related Potential
(ERP) components in the investigation of serotonergic dysregulation in patients
with major depression (review in: Hegerl et al., 2001).
ERPs to auditory stimulation are characterized by three major components: An
electrically positive P1 component at about 50 ms following stimulus onset, a
negative N1 component at 100 ms and a positive P2 component at about 200 ms.
Increases in auditory stimulus intensities are reflected by increases in ERP
amplitudes. Typically, several stimulus intensities are used to elicit amplitude
changes which can be transformed into slope values which give the amplitude
change in µV per 10/dB (Beauducel et al., 2000).
Changes of the N1 and P2 amplitudes, P1/N1 and the N1/P2 peak-to-peak ERP
component amplitudes in response to different tone intensities have been
identified as a correlative of central nervous serotonergic activity (Buchsbaum,
Silverman, 1968; Hegerl et al., 1998; Juckel et al., 1999; Strobel et al., 2003; von
Knorring, Perris, 1981). A high loudness dependent amplitude increase (“high
intensity dependence”, “high IDAP”) presumably reflects low serotonergic
neurotransmission and vice versa (Juckel et al., 1999).
Studies in animals and human individuals corroborated the concept of the IDAP as
an indicator of central serotonergic neurotransmission. Juckel et al. reported
differential effects of microinjection of a 5-HT
1A
agonist and a 5-HT
1A
antagonist
into the dorsal raphe nucleus (DRN) on the intensity dependence of auditory
evoked potentials (AEP) recorded epidurally from the primary and secondary
auditory cortex in behaving cats (Juckel et al., 1999). Strobel et al. (2003) found a
functional polymorphism in the promoter region of the serotonin transporter gene
(5-HTTLPR) to be associated with the N1/P2 amplitude intensity dependence. This
result has been replicated by Hensch et al.(2006). However Debener et al. (2002)
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found no effects of acute tryptophan depletion on AEP N1/P2 amplitude stimulus
intensity function (ASF-slope) in a placebo controlled trial with 18 healthy women,
suggesting that the IDAP might reflect individual rather than state differences of
serotonergic neurotransmission. More recently, Juckel et al. reported an
association between a specific 5-HT1B receptor polymorphism and the loudness
dependence of the N1/P2 component of the auditory evoked potential (Juckel et
al., 2007a).
The psychophysiological phenomenon of augmenting/reducing, firstly described
by Buchsbaum et al. (1968), is assumed to reflect individual differences in the
modulation of sensory input. Individuals who showed an increase of ERP
amplitudes with increasing stimulus intensity were classified as augmenters and
individuals who showed a decrease of ERP amplitudes with increasing stimulus
intensity as reducers. First investigations on the intensity dependence of sensory
evoked potentials and their relation to psychiatric disorders by Zuckerman et al.
(1974) focused on the relation between stimulus intensity dependence and
personality factors like impulsiveness, aggressiveness and sensation seeking
behaviour (Zuckerman, Murtaugh, 1974).
In psychiatric research the role of the IDAP has been studied in several fields:
Juckel et al. found the IDAP of the primary auditory cortex derived from dipole
source analysis in 25 inpatients with schizophrenia to be significantly lower
compared to 25 healthy controls. After treatment with the 5-HT2 antagonistic
antipsychotics clozapine and olanzapine, the IDAP tended to be increased,
indicating normalization of serotonergic function in the patients with
schizophrenia under antipsychotic treatment (Juckel et al., 2003). Tuchtenhagen et
al. (2000) reported a high intensity dependence of auditory evoked dipole source
activity in abstinent ecstasy (MDMA) users which indicates decreased serotonergic
activity (Tuchtenhagen et al., 2000). Similar results have been decribed by Croft et
al. (2001) regarding long-term MDMA abuse. A high IDAP has been described to
correlate with aspects of impulsiveness in 15 female patients suffering from
borderline personality disorder (Norra et al., 2003). Wang et al. found a high IDAP
in histrionic personality disorder (Wang et al., 2006). However, applying dipole
source analysis Senkowski et al. found a significantly lower IDAP derived from
bilateral tangential dipoles in 31 medication-free patients with General Anxiety
Disorder in comparison to 31 matched control subjects (Senkowski et al., 2003). In
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patients under treatment with Serotonin Reuptake Inhibitors (SSRI) Hegerl et al.
(1998) found that high scores in the serotonin syndrome scale (SSS) were
associated with low IDAP and vice versa (Hegerl et al., 1998). Despite the
hypothesised pathophysiological role of serotonin in obsessive compulsive
disorder, Carrillo-de-la-Pena found no difference between patients and controls
(Carrillo-de-la-Pena et al., 2000).
Based on such preclinical and clinical studies, the IDAP has been established as an
electrophysiological indicator of central serotonergic neurotransmission in
depression with special relevance to treatment-response to SSRI. This concept has
been corroborated in several studies applying various antidepressants (Juckel et
al., 2007b; Paige et al., 1994).
As a strong IDAP is considered a predictor of superior response to SSRI treatment
in major depression, this study aims to investigate the hypothesis that the IDAP is
associated with certain patterns of psychometrically assessed symptoms of
depression evaluated by psychiatric rating scales. Moreover we aim to identify,
describe and discuss those psychometric symptoms, which are indirectly
associated with a favourable outcome to SSRI treatment as predicted by a strong
IDAP.
3. Method
3.1 Subjects
Forty in-patients with major depressive episode (DSM-IV: 296.2, 296.3, 296.5; APA
1994), who were admitted consecutively to the Department of Psychiatry and
Psychotherapy of the University of Duisburg-Essen were included in the study. The
study was approved by the local ethics committee. Patients gave their written
informed consent prior to their inclusion in the study. Subjects’ characteristics are
presented in table 1.
3.2 Rating scales and procedure
Symptoms of major depression were assessed by means of psychiatric rating
scales: Clinical Global Impression (CGI) ((NIMH), 1976), Hamilton Rating Scale for
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Depression (HDRS, 21 items) (Hamilton, 1960), Beck Depression Inventory (BDI)
(Beck et al., 1961) and State-Trait-Anxiety Inventory (STAI state anxiety form X1
(Spielberger, 1970)). Symptom ratings were performed by a senior psychiatrist
who had no information on patients' ERP data. The total score of HDRS in patients
had to be 20 at least. The CGI, HDRS and BDI scores were obtained at the day of
ERP recording. Pre-treatment antidepressants were stopped at least two days
before ERP recording. Six patients received antidepressants before they were
included into the study (substance, wash out, duration of treatment: Amitriptyline
n=2, 2 and 3 days, 11 and 8 months; Mirtazapine n=1, 3 days, 5 weeks; Paroxetine
n=1, 2 days, 5 weeks; Venlafaxine n=1, 3 days, 4 weeks; Hypericum extract n=1, 4
days, 4 weeks).Central neurological disorders, abuse of illicit drugs and alcohol
dependence were excluded, as was pre-treatment with electroconvulsive therapy.
Concomitant medication with antipsychotics, mood stabilizers or additional
antidepressants was not allowed. Concomitant benzodiazepine treatment (n=2)
was restricted to a maximum dose of 1.5mg Lorazepam per day. Lorazepam was
not given 12 hours before EEG-recording.
Table 1
Subject characteristics
Total
Age
Gender (m/f)
Education (y)
Nicotine (n; mg/d)
Episodes of depression (n)
Time since the beginning of the first
episode (y)
CGI total score
HDRS total score
HAMA (psychic anxiety)
HAMA (somatic anxiety)
HAMA total score
BDI total score
STAI total score
40
41.9 (± 12.4)
13 / 27
12.8 (± 2.2)
22; 18.3 (± 16.2)
2.2 (± 2.0)
9.0 (± 8.6)
4.6 (± 1.0)
24,5 (±3.8)
6.0 (± 4.9)
3.3 (± 3.1)
8.3 (± 7.6)
28.9 (±12,0)
58.7 (±12.8)
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3.3 Electrophysiological assessment and data analysis
EEG data were recorded in a sound-attenuated and electrically shielded room.
Subjects were seated in a comfortable armchair. Auditory stimulation was done in
two runs of 500 stimuli each with an interstimulus-intervall randomized between
500 ms and 900 ms. Auditory stimuli of 1000 Hz, with 80 ms duration (10 ms rise /
fall) were presented at five intensities of 60, 70, 80, 90 and 100 dB sound pressure
level via TDH-39p headphones (Telephonics Inc.) in randomized order. The
auditory threshold with respect to 1000 Hz tones was below 30 dB as measured by
an audiometer. Stimulus presentation was generated by Neuroscan Stim 3.3
Software. Evoked potentials were recorded from 27 scalp electrodes (extended
international 10-20 system) with linked earlobes as reference using a 32-channel
EEG amplifier (Neuroscan Inc.). A vertical and horizontal electro-oculogram (EOG)
was recorded for offline eyeblink artifact removal (Semlitsch et al., 1986). EEG data
were recorded with a sampling rate of 500 Hz in the frequency range of 0.1 to 100
Hz. ERP data were filtered offline with a 0.1 Hz to 30 Hz bandpass filter (Neuroscan
Edit 4.1). EEG data were segmented into periods of 600 ms starting 100 ms prior to
stimulus onset. Segments with amplitudes exceeding +/- 50 µV were rejected from
further analysis. ERP averages were computed for each stimulus intensity level.
Mean sweep numbers ranged between 114.5 and 137.5 sweeps for intensities
between 60 dB up to 100 dB. Amplitudes of the N1 and the P2 components were
computed from electrodes Fz, Fcz, Cz, C3 and C4. According to Beauducel et al. we
restricted our analysis to those five electrodes which have been most commonly
used in IDAP research (Beauducel et al., 2000).
3.4 Statistical analysis
Intensity slopes (amplitude slope function derived by linear regression across
stimulus intensity levels) were computed for the P1, N1, P2 amplitudes and the
P1/N1 and N1/P2 peak to peak amplitudes. For within-subject tests on stimulus
intensity and electrode effects, epsilon-corrected averaged F-tests (Greenhouse-
Geisser) were used. To assess associations between ERP data and psychometric
symptoms of major depression we restricted correlation analyses to electrode Fz
where we previously found the largest amplitude increases with increasing
auditory stimulus intensity (Linka et al., 2004). With the limitations of a larger
number of relevant symptoms and a sample size of 40 patients we had to abstain
from multivariate analyses. Following Pearson correlations between the N1
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intensity slope at electrode Fz and the sum scores of our psychometric scales, we
screened the single items of our scales (HDRS, BDI, HAMA and STAI) for
correlations with the N1 amplitude intensity slope at electrode Fz. We identified
seven items with significant correlation coefficients (r ≥ .2) between psychometric
rating scales and the IDAP. For the construction of a composite variable, we first
computed z-transformations on each of these seven variables in order to adjust for
different dimensions in scaling between these items. In a second step we averaged
the seven z-transformed single item rating scale scores in each subject, thereby
constructing a composite value. The new composite score values were then
correlated with the N1 amplitude slope data. All statistical analyses were
performed using SPSS.
4. Results
4.1 Rating scales
Results of clinical ratings (Clinical Global Impression, CGI ((NIMH), 1976), Hamilton
Rating Scale for Depression, HDRS, 21 items (Hamilton, 1960), Hamilton Anxiety
Scale, HAMA (Guy, 1976), Beck Depression Inventory, BDI (Beck et al., 1961) and
the State-Trait-Anxiety Inventory, STAI (Spielberger, 1970)) are shown in Table 1.
4.2 ERP data
N1 amplitude intensity slopes were not affected by sex, age, duration of illness,
frequency of depression episodes or smoking habits (Pearson's correlation).
Details on ERP data are given in Table 2.
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Figure 1
N1 evoked potential group averages at electrode Fz. Lines indicate five stimulus
intensity levels ranging from 60 to 100 dB. The amplitude of the N1 component
rises with higher stimulus intensities.
N1 amplitudes and slopes and P1/N1 and N1/P2 slopes were analysed with regard
to electrode position effects in multivariate analysis of variance with electrode as
within factor (Fz, Fcz, Cz, C3, C4) for slopes and electrode and intensity. N1
amplitudes increased with stimulus intensity (F[3.3;202.4] = 28.8, p<.001).
Amplitudes differed between electrode positions (F[1.7;202.4] = 15.1, p<.001) and
there was an interaction between the intensity dependent amplitude increase and
electrode position (F[5.2;202.4] = 2.7, p=.020). Amplitude slopes differed between
electrodes with F[2.1;177.0] = 10.3, p<.001 for the N1, with F[2.1;174.0] = 11.4,
p<.001 for the P1/N1 and with F[2.3;194.0] = 20.8, p<.001 for the N1/P2
component (Table 2).
4.3 Correlations with rating scale items
We found associations of amplitude slopes at electrode Fz with the sum scores of
our psychometric rating scales only for the N1 (HDRS r=-.38, p=.02) but neither for
the P1/N1 nor for the N1/P2 component. There was no significant correlation
between the state of anxiety as measured by the STAI (X1) total score and the
IDAP. In the screening of the single items within the psychiatric rating scales we
found highly significant correlations with the intensity slopes of the N1 amplitude
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at Fz: HAMA item “Depressed Mood” (decreased interest in activities, anhedonia,
insomnia): r=.41, p=.008, BDI item “Lack of interest in sex“: r=.40, p=.010 and
HDRS items “insomnia, early“: r=.40, p=.011 and “decreased libido or menstrual
disturbance”: r=.33, p=.037 correlated positively with the IDAP. There was a
statistical trend for a positive correlation for BDI items “hopelessness”: r=.29,
p=.073 and “decreased appetite”: r=.28, p=.079 and HDRS item “weight loss”:
r=.26, p=.10. The overall correlation for these 7 rating scale items was r=.64,
p<.001 (Fig. 2).
Figure 2
Scatterplot of overall correlation for 7 rating scale items with intensity dependent N1
amplitudes increase (slopes at µV / 10 dB) r=.64, p<.001.
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Table 2
ERP Data: N1 amplitudes and N1, P1/N1, N1/P2 amplitude slopes.
n=40
mean (sd)
N1 amplitude 60 dB / 100 dB (µV)
*
Fz
Fcz
Cz
C3
C4
–3.22 (±2.0); –5.87 (±3.5)
–3.28 (±1.9); –6.04 (±3.0)
–3.09 (±1.9); –5.65 (±2.8)
–2.94 (±1.8); –5.34 (±2.6)
–2.89 (±1.6); –5.02 (±2.5)
N1 amplitude slope (µV/10 dB)
#
Fz
Fcz
Cz
C3
C4
0.67 (±0.52)
0.71 (±0.46)
0.66 (±0.43)
0.61 (±0.39)
0.55 (±0.39)
P1/N1 amplitude slope (µV/10 dB)
#
Fz
Fcz
Cz
C3
C4
0.73 (±0.51)
0.83 (±0.54)
0.81 (±0.54)
0.67 (±0.50)
0.76 (±0.47)
N1 / P2 amplitude slope (µV/10 dB)
#
Fz
Fcz
Cz
C3
C4
0.64 (±0.61)
0.85 (±0.70)
0.88 (±0.74)
0.70 (±0.56)
0.67 (±0.56)
*
Evoked response (ERP) amplitude data are given in µV for the lowest (60 dB) and the
highest (100 dB) auditory stimulus intensities at electrode positions Fz, Cz, Fcz, C3 and C4.
#
Amplitude slopes give the absolute value of the mean increase in ERP amplitudes within
the five (60, 70, 80, 90 and 100 dB) stimulus intensities in µV per 10 dB.
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5. Discussion
Our analysis revealed a significant correlation between the intensity dependent
slope of the N1 raw amplitude and specific symptoms assessed by means of
psychiatric rating scales in unmedicated depressive subjects. We especially aimed
to investigate the hypothesis of the IDAP being associated with certain patterns of
psychometric symptoms of major depression and to identify, describe and discuss
those symptoms, which may thus be indirectly associated with the outcome to
SSRI treatment. In healthy subjects, the IDAP has been assessed and associated
with personality traits by other authors. As this study focuses on the analysis of
psychometric symptoms of major depression, we abstained from the assessment
of healthy control subjects.
Among those six patients, who had been pretreated with antidepressants two
subjects actually had a wash out phase of two days, whereas three subjects had a
wash out phase of three days and one subject of four days. Exclusion of these
pretreated subjects from evoked potential data analysis did not reveal significant
differences in comparison to the analysis of the whole patient sample. Therefore
we abstained from excluding these subjects from our analysis.
While several previous studies applied reverse problem solutions like BESA or
LORETA in the evaluation of the N1/P2 auditory intensity dependence (Gallinat et
al., 2000, Tuchtenhagen et al., 2000, Mulert et al., 2002) other studies evaluated
raw data with regard to N1 (Brocke et al., 2000, Strobel et al., 2003), N1/P2
(Strobel et al., 2003, Croft et al., 2001) and P2 (Paige et al., 1994) amplitude
slopes. In line with our earlier studies, here we investigated auditory stimulus
intensity with regard to raw data P1, P1/N1, P2, N1 and N1/P2 amplitude slopes.
We found associations of amplitude slopes at electrode Fz with psychometric
symptoms of depression only for the N1 but neither for the P1/N1 nor for the
N1/P2 component.
The intensity dependent amplitude slopes of the subjects in our study are
comparable with those obtained in previous studies using similar procedures and
measures. While our inter-stimulus interval between 500 ms and 900 ms is at the
lower end of what has been used by other groups, stimulus intensities, electrode
positions and stimulus intensity slope calculation are in keeping with previously
employed methods (Beauducel et al., 2000). The resulting N1/P2 amplitude slopes
in our study are in line with results reported by Sandor et al. (1999). They are
however lower than those reported by Croft et al. (2001) and higher than those in
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a study by Proietti-Cecchini et al. (1997). Therefore we may conclude that our
experimental setup is principally comparable with that applied in previous studies
in this field. However, the result that our data revealed no significant associations
between psychometric symptoms of depression and P1/N1, N1/P2 and P2 slopes
may be attributed to characteristics of our paradigm. In our data the N1 amplitude
slope at electrode Fz slope was significantly correlated with the N1/P2 (r=.57,
p<.001), with the P1/N1 (r=.65, p>.001) but to a much lower degree with the P2
(r=.32, p=.043). We suggest that in our experimental setup the N1 is the most
sensitive variable. This is in line with our previous reports using the same
experimental setup (Linka et al., 2004; Linka et al., 2005) .
We found 7 rating scale items to correlate with more than r = 0.2 with the IDAP.
The correlation of the composite score of these 7 items was statistically highly
significant with r = .64. The composite score can be viewed at as a construction of
a kind of questionnaire derived from the pool of questions obtained in our study.
The fact, that the correlation of the composite score with the N1 amplitude slope
is considerably higher than each of the correlations with the single items may be
taken as indirect evidence for the relevance of the selected items. The first four of
these single items correlated significantly with the IDAP while the latter three
showed statistical trends. Of special relevance are those items which tag
congruent symptoms from psychiatrist’s assessment (HDRS) as well as from
patients self rating (BDI). Here, this applies to HDRS item “decreased libido or
menstrual disturbance” and BDI item “lack of interest in sex” as well as to HDRS
item “weight loss” and BDI item “decreased appetite”.
The correlation of BDI item “Lack of interest in sex“ and HDRS item “decreased
libido or menstrual disturbance” points to the important finding, that a high score
in sexual disturbance in patients self rating as well as in psychiatrists rating was
associated with a high IDAP. This finding is of special clinical interest as a high IDAP
correlates with a favorable response to SSRI-treatment (Gallinat et al., 2000; Paige
et al., 1994) and the existence of sexual dysfunction associated with depression
has so far not been described as a criterion for pharmacotherapy with an SSRI.
However, our finding seems to be in contrast to a study results suggesting a
benefit for depressive patients with sexual dysfunction when treated with
Reboxetine (Clayton et al., 2003). In line with the latter result, many clinicians tend
to avoid SSRI in the treatment of major depression associated with sexual
disturbances. On the other hand a recent study by Cyranowksi et al (2004) found
that SSRI induced sexual dysfunction in a group of 68 women treated for recurrent
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major depression was restricted to orgasmic difficulty only, whereas libido and
sexual interest were related to depression itself (Cyranowski et al., 2004). As a
consequence of our findings, future studies might evaluate the hypothesis, that
the existence of sexual dysfunction (apart from orgasmic difficulty) in major
depressive episodes may be one among other criteria for treatment with SSRI.
While the effects of SSRI-treatment on appetite and weight are still under
discussion (Harvey, Bouwer, 2000), the statistical trend in the correlation between
high IDAP indicating favorable SSRI treatment response (Gallinat et al., 2000; Linka
et al., 2004) and high scores in BDI items “decreased appetite” and HDRS item
“weight loss” is of interest as it implies that the presence of these symptoms may
be an indicator for successful SSRI treatment of major depression. However,
considering the low statistical association of this finding, this hypothesis may be
taken as preliminary.
The statistically significant correlation between high IDAP and a high score in HDRS
item “insomnia, early“ is of clinical relevance because insomnia is closely related
to depressive symptomatology (Fava, 2004). Insomnia has also been reported as a
frequent side-effect in SSRI treatment of major depression (Ferguson, 2001). Our
finding might give indirect support to the clinical practice of continuing SSRI
treatment despite a temporary worsening of sleep disturbance.
In summary, the results of our study may contribute to a more specific clinical
basis in the differential indication of serotonergic versus noradrenergic
antidepressants and indicate an association of specific somatic symptoms of major
depression with the IDAP. While or study is exploratory, further studies are
needed to further assess and verify the relevance of our findings. Moreover,
studies combining ERP, genetic approaches (NET- and 5HT-polymorphisms) and
clinical symptomatology in a double blind, randomized setting with different
classes of antidepressants (SSRI, NARI, SNRI) are needed.
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STIMULUS INTENSITY DEPENDENT ERP COMPONENTS IN THE
PHARMACOTHERAPY OF MAJOR DEPRESSIVE DISORDER
CHAPTER 6
TREATMENT EFFECTS OF
SEROTONERGIC AND
NORADRENERGIC ANTIDEPRESSANTS
ON THE INTENSITY DEPENDENCE OF
AUDITORY ERP COMPONENTS IN
MAJOR DEPRESSION.
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Abstract
The intensity dependent amplitude change of auditory evoked potentials (IDAP),
an assumed indicator of the level of central nervous serotonergic
neurotransmission, was measured in major depressive disorder (MDD, DSM-IV:
296.2, 296.3; APA 1994) before and after treatment with either a selective
serotonin reuptake inhibitor or a selective noradrenaline reuptake inhibitor
antidepressant and compared with the results of a healthy control group. Auditory
evoked P1, N1, P2, P1/N1 and N1/P2 peak-to-peak amplitudes were evaluated in
26 in-patients with MDD prior to and after antidepressant treatment with
citalopram (24 days, n = 14) or reboxetine (25 days, n = 12), and in 43 healthy
control subjects. Clinical symptoms of MDD were assessed by means of
standardized psychiatric rating scales (CGI, HDRS, HAMA and BDI). The IDAP within
the control group remained stable over 24 days (N1 amplitude slope retest ANOVA
p = .79). Neither applied antidepressants nor decrease of HDRS total score during
treatment had a significant effect on the IDAP in the patients’ sample. The
conclusion that the IDAP does not reflect the temporary depressive state in MDD
is discussed.
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Despite significant advances in pharmacologic treatment of major depressive
disorder (MDD) over the past 20 years, a substantial proportion of patients (28 -
55%) fail to respond sufficiently to the treatment with the newer serotonin re-
uptake inhibitor (SSRI) antidepressants, which have been introduced in the late
1980s [1]. Based on current main pathophysiological concepts of MDD, which
comprise alterations in the central serotonergic neurotransmission and sensitivity
[2], several authors within the field of human electrophysiology research focused
on auditory event related potential (ERP) components in the investigation of
serotonergic dysregulation in patients with MDD [3].
The ERP to auditory stimulation consist of three major components: the
electrically positive P1 component at about 50 ms following stimulus onset, the
negative N1 component at about 100 ms and the positive P2 component at about
200 ms. Typically, increases in auditory stimulus intensities result in increases of
these ERP amplitudes. Several stimulus intensities are used to elicit amplitude
changes, which can be transformed into slope values rendering the amplitude
change in µV per 10/dB [4].
The degree of increase of N1 and P2 amplitudes as well as P1/N1 and the
N1/P2 peak-to-peak ERP component amplitudes in response to different tone
intensities has been identified as a correlative of central nervous serotonergic
activity [5,6]. Animal [7,8], preclinical [9,10] and clinical studies have shown that a
high intensity (loudness) dependent amplitude increase (“high intensity
dependence”, “high IDAP” or “high LDAEP”) presumably reflects low central
serotonergic neurotransmission and vice versa. A negative result came from Uhl et
al., who measured the IDAP in female subjects under infusion of citalopram versus
placebo and performed dipole source analysis. The increase of the central
serotonin activity in response to citalopram was not accompanied by a significant
change of the IDAP compared to the placebo condition [11]. The latter result is in
line with an amino acid depletion study by Norra et al. in 16 healthy females.
While monitoring tryptophan levels and mood states, the AEP of different
loudness stimuli were recorded, followed by dipole source analysis. Calculated
IDAP did not differ significantly between treatments and the IDAP was not
correlated with states of mood, suggesting that the IDAP might reflect individual
(trait) rather than state differences of serotonergic neurotransmission [12].
The concept of the IDAP as an indicator of central nervous serotonergic
neurotransmission in MDD has been evaluated with positive results in various
studies applying different antidepressants [13,14,15,16]. However, Guille et al.,
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who used a double-blind, placebo-controlled cross-over design, in which healthy
subjects were tested under acute treatment with pharmacologically equivalent
single doses of placebo, escitalopram, citalopram and sertraline and applied two
methods of ERP analysis (dipole source analysis and scalp analysis), found no
effects of the applied antidepressants on the IDAP [17].
Table 1
Subject characteristics
MDD, citalopram
treatment sample;
means (SD)
MDD, reboxetine
treatment sample;
means (SD)
Control
sample;
means (SD)
n
Age
Gender (m/f)
Education (y)
Nicotine (n; mg/d)
Episodes of depression (n)
Duration of illness (y)
Dose of antidepressant (mg)
CGI total score (baseline)
CGI total score (day 25/24)
HDRS total score (baseline)
HDRS total score (day 25/24)
BDI total score (baseline)
BDI total score (day 25/24)
14
39.38 (±14.5)
5/11
13.0 (±2.6)
9; 12.9 (6.3)
2.37(±1.7)
8.3 (±7.3)
37.5 (±10.0)
4.56 (±0.7)
3.9 (±0.8)
25.13 (±3.5)
14.6 (±5.5)
29.50 (±12.5)
21.6 (11.0)
12
45.2 (±11.8)
4/10
12.9 (±2.0)
6; 14.9 (±20.4)
2.7(±2.4)
10.0 (±8.6)
8.4 (±10.0)
4.6 (±1.4)
3.4 (±1.1)
24.1 (±3.7)
11.6 (±7.2)
23.7 (±10.6)
15.4 (±10.7)
43
39.2 (±
10.4)
16/27
13.9 (± 2.6)
22; 14.11
(± 9.2)
-
-
-
-
3.1 (±3.1)
3.3 (±3.0)
Although several reports from independent laboratories considered the
IDAP as a pre-treatment indicator in the pharmacologic therapy of MDD and
examined acute effects of serotonergic antidepressants, the impact of different
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antidepressants applied over several weeks and the effects of the course of
treatment of MDD on the IDAP are still unclear. In the present study, we assessed
the IDAP in MDD before and after 24 days of treatment with either the selective
serotonin reuptake inhibitor citalopram or the selective noradrenaline reuptake
inhibitor reboxetine and compared the results with that of a healthy control
group.
The essential aim of our study was to investigate, whether serotonergic
and non-serotonergic antidepressants differentially influence the IDAP itself.
Furthermore we aimed to evaluate, whether the pre-treatment IDAP changes in
the course of treatment of MDD and thus shows an association with the degree of
the clinically observed depressive state.
Twenty-six in-patients with MDD (DSM-IV: 296.2, 296.3; APA 1994; diagnosed by
structured clinical interviews), who were admitted consecutively to the
Department of Psychiatry and Psychotherapy of the University of Duisburg-Essen
and 43 matched healthy control subjects, were included for participation in the
study. Patients and controls gave their written informed consent prior to their
inclusion in the study. The study was approved by the local ethics committee and
performed in accordance with the ethical recommendations laid down in the
Declaration of Helsinki. Control subjects were matched with regard to age, and
gender with the patient sample. Patients and controls did not differ significantly
with regard to age and gender (table 1).
Central neurological disorders, hearing disability, abuse of illicit drugs and
alcohol dependence were excluded, as was pre-treatment with electroconvulsive
therapy during the last six months before inclusion. Subjects with a history of
other axis-I-disturbances (DSM-IV) than depressive disorders were not included.
Concomitant medication with antipsychotics, mood stabilizers or additional
antidepressants was not allowed.
Clinical symptoms of major depression were assessed by means of
psychiatric rating scales: Clinical Global Impression (CGI) [18], Hamilton Rating
Scale for Depression (HDRS, 21 items, range of scores: 0 - 63) [19] and Beck
Depression Inventory (BDI, 21 items, range of scores: 0 - 63) [20]. Clinical ratings
were performed by an experienced senior psychiatrist who was blind to patients'
ERP data. The BDI self rating scale was completed by all subjects in order to
exclude individuals with clinically relevant depression within the control group.
The pre-treatment total score of HDRS had to be 20 at least for patients to be
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included into the study. The CGI, HDRS and BDI scores were obtained on the day of
pre-treatment EEG-recording and after a mean of 24 days of treatment with either
citalopram or reboxetine. According to the study protocol pre-treatment
antidepressants had to be stopped at least 2 days before EEG-recording. Actually
four patients of our sample received antidepressants during the last 12 months
before they were included into the study (substance, duration of treatment, wash
out period: amitriptyline n=1, 8 months, 11 months; mirtazapine n=1, 5 weeks, 3
days; venlafaxine n=1, 4 weeks, 3 days; hypericum extract n=1, 4 weeks, 4 days),
which implicates that the minimal wash out time was 3 days. Concomitant
benzodiazepine treatment (n=2) was restricted to a maximum dose of 1.5 mg
lorazepam per day. Lorazepam was not given 12 hours before EEG-recording.
EEG-recording was repeated in a sub-sample of 14 patients (11 women, 3
men), who had been chosen for therapy with an SSRI antidepressant for clinical
reasons, after 25 days of treatment (mean) with citalopram (free dose chosen
within a range of 20 - 40 mg per day) and in another sub-sample of 12 patients (10
women, 2 men), who were considered as candidates for an antidepressive
medication with a non-serotonergic antidepressant, after 24 days of treatment
(mean) with reboxetine (free dose chosen within a range of 6 - 12 mg per day). The
control individuals underwent EEG-recording two times as well, with an interval of
28 days.
EEG data were recorded in a sound-attenuated and electrically shielded
room. Subjects were seated in a comfortable armchair. Auditory stimulation was
administered in two runs of 500 stimuli each with an interstimulus-interval
randomized between 500 ms and 900 ms. Auditory stimuli of 1000 Hz, with 80 ms
duration (10 ms rise / fall) were presented at five intensities of 60, 70, 80, 90 and
100 dB sound pressure level via TDH-39p headphones (Telephonics Inc.) in
randomized order. The auditory threshold with respect to 1000 Hz tones was
below 30 dB as measured by an audiometer. Stimulus presentation was generated
by Neuroscan Stim 3.3 Software. Evoked potentials were recorded from 27 scalp
electrodes (extended international 10-20 system) with linked earlobes as
reference using a 32-channel EEG amplifier (Neuroscan Inc.). A vertical and
horizontal electro-oculogram (EOG) was recorded for offline eye blink artifact
removal. EEG data were recorded with a sampling rate of 500 Hz in the frequency
range of 0.1-100 Hz. ERP data were filtered offline with a 0.1-30 Hz band pass filter
(Neuroscan Edit 4.1). EEG data were segmented into periods of 600 ms starting
100 ms prior to stimulus onset. Segments with amplitudes exceeding +/- 50 µV
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were rejected from further analysis. ERP averages were computed for each
stimulus intensity level. Mean sweep numbers ranged between 114.5 and 137.5
sweeps for intensities between 60 and 100 dB. Amplitudes of the N1 and the P2
components were computed from electrodes Fz, FCz, Cz, C3 and C4. In accordance
with Beauducel et al. we restricted our analysis to those five electrodes which
have been most commonly used in IDAP research [4].
Pre-treatment ERP amplitude of the P1, N1, P2 amplitudes and the P1/N1
and N1/P2 peak-to-peak amplitudes were analysed in separate multivariate
analyses of variance with stimulus intensities (60, 70, 80, 90, 100 dB) and
electrodes (Fz, FCz, Cz, C3, C4) as within factors and group (patients / control) as
between factor. Effects of gender, and smoking habit on amplitude slopes were
assessed with Chi² tests and the effects of age, education and the amount of
nicotine consumption among smoking subjects were assessed with analysis of
variance. The impact of duration of illness and the frequency of depression
episodes on evoked potentials were assessed with Pearson’s correlations.
Detailed results of clinical ratings are presented in table 1. Patients and
controls did not show significant group differences with regard to age, gender,
smoking status and the amount of nicotine intake per day in smoking subjects.
However, patients reported fewer years of education than control subjects (p =
.015). Within the control group BDI total scores did not reveal any significant
symptoms of affective disorder and there was no significant difference between
the first and the second ERP measurement.
Results from clinical ratings within the citalopram treatment group:
psychiatric rating scores improved significantly from baseline to retest after a
mean of 25 days of treatment: HDRS total score decreased from 25.1 (±3.5) to 14.6
(±5.5), BDI total score decreased from 29.5 (±12.5) to 21.6 (11.0) and CGI severity
of illness score decreased from 4.6 (±0.7) to 3.9 (±0.8) as presented in table 1. A
multivariate analysis of variance including the HDRS and the BDI at baseline and
day 25 (time factor) revealed a significant main effect for the time factor (F=38.5,
p<.001). The amount of symptom reduction did not differ between patients’ self-
ratings (BDI) and psychiatrist’s ratings (HDRS) as indicated by the lack of a
significant time x scale interaction.
Results from clinical ratings within the reboxetine treatment group:
Psychiatric rating scores significantly improved from baseline to follow-up after a
mean of 24 days of treatment: HDRS total score decreased from 24.1 (±3.7) to 11.6
(±7.2), BDI total score from 23.7 (±10.6) to 15.4 (±10.7) and CGI severity of illness
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score from 4.9 (±0.5) to 3.4 (±1.1) as presented in Table 1. A multivariate analysis
of variance including the HDRS and the BDI (scale factor) at baseline and day 24
(time factor) revealed a significant main effect for the time factor (F=44.8, p<.001).
The amount of symptom reduction did not differ between patients’ self-ratings
(BDI) and psychiatrist’s ratings (HDRS) as indicated by the lack of a significant time
x scale interaction.
General results from the ERP data analysis: N1 amplitude intensity slopes
within the control group were not affected by sex, age or smoking habits
(Pearson's correlation). Details on ERP data of patients and controls are given in
figure 1 and in table 2. N1 amplitudes increased with stimulus intensity
(F[3.3;202.4] = 28.8, p<.001). Amplitudes differed between electrode positions
(F[1.7;202.4] = 15.1, p<.001) and there was an interaction between the intensity
dependent amplitude increase and electrode position (F[5.2;202.4] = 2.7, p=.020).
Amplitude slopes differed between electrodes with F[2.1;177.0] = 10.3, p<.001 for
the N1, with F[2.1;174.0] = 11.4, p<.001 for the P1/N1 and with F[2.3;194.0] =
20.8, p<.001 for the N1/P2 component.
The IDAP within the control group remained stable over 4 weeks (N1
amplitude slope retest ANOVA p = .79).
Following a mean treatment period of 25 days with citalopram or 24 days
with reboxetine, respectively, N1 amplitude slopes correlated no longer with
clinically observed depression (HDRS total score).
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Figure 1
The N1 amplitude at electrode Fz before (pre) and after (post) antidepressant
treatment with either citalopram or reboxetine (MDD only). Group differences
between MDD patients and controls are not statistically significant.
ERP results within the citalopram treatment group: pre-treatment intensity slopes
of the N1 amplitudes correlated significantly with HDRS reduction at Fz (r=0.56,
p=.025) at FCz (r=0.55, p=.00.29) and at Cz (r=0.50, p=0.048). No correlations with
HDRS reduction were found for N1 amplitude slopes from C3 to C4. N1 amplitude
intensity slopes were not affected by sex, age, duration of illness, frequency of
episodes of depression, smoking habits (Pearson's correlation). No correlation
emerged for N1 intensity slopes with BDI and CGI scores. Additionally, no
correlations with psychiatric ratings were found for P1, P1/N1, P2 and N1/P2
amplitude slopes. After a mean of 25 days of pharmacologic treatment with
citalopram, the N1 amplitude slope at Fz correlated no longer with HDRS reduction
(r = -0.19, p = 0.56). We found no group main effect or interactions involving the
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group factor when comparing citalopram treated patients with the control group
over time.
ERP results within the reboxetine treatment group: we found highly
significant correlations of low intensity slopes of the N1 and high HDRS reduction
at Fz (r=.86, p<.001) at FCz (r=.91, p<.001), at Cz (r=.93, p<.001), C3 (r=.81, p<.001)
and C4 (r=.75, p<.001). Lower intensity slopes of the N1 amplitude were associated
with better outcome as indicated by reduction of HDRS scores after treatment. N1
amplitude intensity slopes were not affected by sex, age, and duration of illness,
frequency of depression episodes or smoking habits (Pearson's correlation).
Significant correlations (Pearson's) with HDRS reduction were found for P1/N1
peak-to-peak amplitude slopes at Fz (r=.68, p<.001) at FCz (r=.63, p=.015), at Cz
(r=.56, p=.038) and C3 (r=.63, p=.017) and N1/P2 amplitude slopes at Fz (r=.70,
p<.001) and at FCz (r=.56, p=.036). No correlations emerged from the assessment
of P2 amplitude slopes or from ERP intensity slopes and BDI or CGI scores. After a
mean of 24 days of pharmacologic treatment with reboxetine N1 amplitude slope
at Cz no longer correlated with HDRS (r = -0.27, p = 0.40). We found no group main
effect or interactions involving the group factor when comparing reboxetine
treated patients with the control group over time.
In the present study, we evaluated the intensity dependence of different auditory
ERP components in MDD before and after a mean period of 25 days and 24 days,
respectively, of pharmacologic treatment with either the selective serotonin
reuptake inhibitor citalopram or the selective noradrenaline reuptake inhibitor
reboxetine and compared the results with that of a healthy control group.
Based on several clinical studies, we assumed that patients with a high
pre-treatment IDAP might belong to a pathophysiological subtype of MDD, which
might be characterized by a low central nervous serotonergic metabolism, and
therefore is likely to show a favourable response to SSRI treatment [13, 14]. This
assumption led to our hypothesis that the successful treatment with an SSRI
antidepressant might bring about a normalization of a pathologically low pre-
treatment central nervous serotonergic activity in MDD.
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Table 2
N1 amplitudes and N1, P1/N1, N1/P2 amplitude slopes in major depressive disorder before
and after antidepressant treatment with either citalopram or reboxetine.
MDD pre-treatment
mean (SD)
MDD post-treatment
mean (SD)
citalopram treatment group (n=14)
N1 amplitude
60 dB / 100 dB (µV)
a
Fz
Fcz
Cz
–2.80 (±2.0) / –6.13 (±3.8)
–2.85 (±2.1) / –6.26 (±3.0)
–2.77 (±2.2) / –5.73 (±2.8)
–3.14 (±1.9) / –5.50 (±2.9)
–3.19 (±1.9) / –6.21 (±2.2)
–3.10 (±2.1) / –5.8 (±2.2)
N1 amplitude slope
(µV/10 dB)
b
Fz
Fcz
Cz
0.83 (±0.5)
0.85 (±0.5)
0.76 (±0.4)
0.58 (±0.4)
0.75 (±0.4)
0.70 (±0.4)
P1/N1 amplitude slope
(µV/10 dB)
b
Fz
Fcz
Cz
1.02 (±0.6)
0.91 (±0.6)
0.74 (±0.6)
0.98 (±0.6)
1.14 (±0.6)
1.17 (±0.5)
N1 / P2 amplitude
slope (µV/10 dB)
b
Fz
Fcz
Cz
0.68 (±0.7)
0.88 (±0.8)
0.87 (±0.8)
0.93 (±0.4)
1.15 (±0.4)
1.17 (±0.5)
reboxetine treatment group (n=12)
N1 amplitude
60 dB/100 dB (µV)
a
Fz
Fcz
Cz
–3.38 (±1.8) / –5.74 (±3.6)
–3.57 (±1.8) / –5.94 (±3.3)
–3.48 (±1.7) / –5.78 (±3.3)
–3.28 (±1.8) / –6.10 (±2.8)
–3.50 (±1.8) / –6.55 (±2.8)
–3.39 (±1.7) / –6.22 (±2.9)
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a
Evoked response (ERP) amplitude data are given for the lowest (60 dB) and the highest (100
dB) auditory stimulus intensities at electrode positions Fz, Cz, Fcz in µV.
b
Amplitude slopes give the absolute value of the mean increase in ERP amplitudes within
the five (60, 70, 80, 90 and 100 dB) stimulus intensities in µV per 10 dB.
Moreover, patients with MDD who show a low pre-treatment IDAP in
comparison to a healthy control group have been found to respond favourably to
non-serotonergic, e.g. noradrenergic antidepressants [15]. Considering the
pathophysiological concepts of MDD comprise a presumed imbalance of central
nervous noradrenergic and serotonergic activity, any successful treatment is likely
to be accompanied by or result from a normalization of a presumably disturbed
central nervous serotonergic and noradrenergic balance. Thus, we assumed that a
low IDAP within the subgroup of MDD patients who favourably respond to
reboxetine should also show increasing similarity with the healthy control group in
the course of treatment.
reboxetine treatment group (n=12)
N1 amplitude slope
(µV/10 dB)
b
Fz
Fcz
Cz
0.57 (±0.6)
0.58 (±0.5)
0.57 (±0.5)
0.67 (±0.4)
0.75 (±0.5)
0.71 (±0.5)
P1/N1 amplitude slope
(µV/10 dB)
b
Fz
Fcz
Cz
0.60 (±0.5)
0.64 (±0.5)
0.68 (±0.6)
0.91 (±0.6)
1.01 (±0.6)
0.97 (±0.6)
N1 / P2 amplitude
slope (µV/10 dB)
b
Fz
Fcz
Cz
0.59 (±0.6)
0.72 (±0.6)
0.80 (±0.6)
0.66 (±0.7)
0.78 (±0.7)
0.74 (±0.7)
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The results of our investigations did not confirm our hypotheses, because
they suggest that neither serotonergic medication with citalopram itself nor
treatment effects as measured by an increase in HDRS total score in the
reboxetine treatment subgroup had a significant effect on the IDAP in the course
of treatment.
Considering methodological aspects of our ERP data analysis, we may say
that the intensity dependent amplitude slopes of the subjects in our study are
comparable with those obtained in previous studies using similar procedures and
measures. While our inter-stimulus interval is at the lower end of what has been
used by other groups, stimulus intensities, electrode positions and stimulus
intensity slope calculation are in keeping with previously employed methods [4].
The resulting N1/P2 amplitude slopes of our study are similar to the results
reported by Sandor et al. [21]. In line with our earlier studies, we investigated
auditory stimulus intensity with regard to raw data ERP amplitude slopes as did
many previous studies (N1 [9], N1/P2 [9, 23], P2 [21]). Our relatively small patient
samples are an important limitation of our study. However, applying raw data
analysis of single electrodes, a high test-retest reliability retest-stability of the IDAP
after about 3 weeks of .71, .77 and .59 at Cz, C3, C4, respectively, in a sample
including 8 men and 16 women (mean age = 47, SD = 11) has been demonstrated
[4]. Nevertheless, the detection of statistically smaller treatment effects on the
IDAP might require larger samples.
Further limitations result from the open-label and treatment-as-usual
design of our study due to the ethical problems a double-blind randomized design
with fixed doses of the applied antidepressants bring about in the research with
patients, who suffer from clinically relevant depressive disorders. Furthermore,
we did not control the female subjects of our samples for menstrual cycle and
associated hormonal fluctuations, which have been shown to affect auditory ERP
components [24] and did not perform any control procedure for possible attention
effects on the IDAP [26].
The lack of treatment effects on the IDAP in the course of our evaluation
indicates that the IDAP is not significantly associated with the current depressive
state in MDD. This conclusion is in line with several studies which demonstrated a
considerable degree of heritability of the IDAP [21] and reported an association of
the IDAP with 5-HTTLPR, a genetic polymorphism of the revealed serotonin
transporter coding gene [9, 10, 25]. Moreover, our results harmonize with recent
studies by Guille et al. [17], who found no effects of acute treatment with various
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SSRI on the IDAP, and by Norra et al. [12], who found no correlation of the IDAP
with acute tryptophan depletion and with states of mood in healthy subjects.
The results of our study revealed that serotonergic as well as
noradrenergic antidepressant treatment over more than 3 weeks were not
associated with significant change in the IDAP in MDD. This finding does not
contradict the concept of the IDAP as a pre-treatment indicator of treatment-
response to serotonergic versus non-serotonergic antidepressants, but suggests
that the IDAP may not reflect the individual depressive state. The latter
assumption implies that treatment-success in MDD does not go along with a
‘normalization’ of the IDAP. However, further studies with a larger sample and
with control for the above mentioned methodological aspects are needed to give
more evidence on this question.
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1. Introduction
In this research project, the stimulus intensity dependence of auditory evoked
potentials (IDAP) of several ERP components in patients suffering from major
depressive disorder (MDD) and in healthy control subjects was investigated. We
assessed the predictive value of the IDAP for treatment with the SSRI citalopram
(Chapter 2), as well as for treatment with the selective norepinephrine re-uptake
inhibitor (SNRI) reboxetine in MDD (Chapter 3). We compared the IDAP of auditory
ERP components in unmedicated patients with MDD with the results from healthy
controls (Chapter 4) and evaluated treatment effects of serotonergic and
noradrenergic antidepressants in MDD on the IDAP itself (Chapter 6).
Furthermore, we studied associations of certain clinical symptoms of MDD with
auditory ERP components (Chapter 5).
2. The IDAP as a predictor of response to citalopram and
reboxetine treatment in patients with MDD
The results of the study evaluating the IDAP in 16 in-patients with MDD during the
course of treatment with the SSRI citalopram revealed a significant correlation
between the intensity slopes of the N1 amplitude prior to citalopram-treatment
and treatment-response: patients with higher intensity slopes of N1 amplitude
showed a significantly stronger decrease of HDRS-Score after citalopram-
treatment than patients within the lower intensity slope ranges. A second study
comprising 14 in-patients with MDD during treatment with the SNRI reboxetine
demonstrated a highly significant correlation between lower pre-treatment
intensity dependent N1 amplitude slopes and stronger decrease of HDRS total
score.
In both treatment conditions, we investigated auditory stimulus intensity with
regard to raw data of P1, P1/N1, P2, N1 and N1/P2 amplitude slopes, although
according to the theory of Hegerl et al. (1993), the IDAP should be ideally assessed
in the primary auditory cortex. In human studies, the latter can indirectly be done
by using multichannel-EEG combined with source analysis techniques such as Brain
Electrical Source Analysis (BESA; Scherg and Von Cramon, 1986) or Low Resolution
Electromagnetic Source Analysis (LORETA; Pascual-Marqui et al., 1994). However,
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many previous studies applied scalp analysis with regard to N1 (Brocke et al.,
2000, Strobel et al., 2003), N1/P2 (Strobel et al., 2003, Croft et al., 2001) or P2
(Paige et al., 1994) amplitude slopes.
In both efficacy prediction studies, highly significant associations of ERP amplitude
slopes with treatment outcome were found, predominantly for the N1 amplitude
and to a lesser extent for P1/N1 and the N1/P2 component as well, but not for the
P2 component. This result contrasts with a study by Paige et al. (1994), who found
a significant correlation of P2 amplitude intensity dependence with SSRI treatment
outcome and with Beauducel et al. (2000), who suggested that the P2 amplitude
slopes may reflect stimulus intensity changes more precisely than other ERP
component slopes.
The negative results of the IDAP derived from the P2 amplitude slope in our
studies might be due to the relatively small samples. Considering the high split-half
coefficients in our studies, indicating high internal consistency of ERP data and
intensity slopes, comparable to previously reported studies, it seems unlikely that
our studies might lack from data quality. Methodological studies of the IDAP, using
raw data analysis from single electrodes, detected reliabilities between r =.7 and .8
(Beauducel et al., 2000). A study by Dierks et al. (1999) using an acute tryptophan
depletion paradigm, revealed a high correlation of the IDAP of tangential dipoles
with the IDAP at Cz. Recently, Guille et al. (2008), who used a double-blind,
placebo-controlled cross-over design in which healthy subjects were tested under
acute treatment with pharmacologically equivalent single doses of placebo,
escitalopram, citalopram and sertraline and applied two methods of ERP analysis
(dipole source analysis and scalp analysis), revealed similar results for both
assessment strategies(dit is wel een erg lange zin). In conclusion, the IDAP has
been shown to be a clinically relevant indicator a central nervous serotonergic
activity, that can be reliably assessed by the easily applicable, conventional scalp
analysis of ERP.
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3. Treatment effects of antidepressants on the IDAP in major
depression
We postulated that patients with a high pre-treatment IDAP might belong to a
pathophysiological subtype of MDD characterized by a low central nervous
serotonergic metabolism, and therefore are likely to show a favourable response
to SSRI treatment (Gallinat et al., 2000, Linka et al., 2004). This assumption led to
the hypothesis that a successful treatment with an SSRI might bring about a
normalization of a pathologically low pre-treatment central nervous serotonergic
activity in MDD. Thus, we expected that treatment with citalopram should lead to
a decrease of a heightened pre-treatment IDAP. Furthermore, we postulated that
a low IDAP within the subgroup of MDD patients who favorably respond to
reboxetine, should also show increasing similarity with the healthy control group
during the course of treatment, i.e., that an increase of a low pre-treatment IDAP
under pharmacotherapy with reboxetine should be due to an improvement of the
depressive state rather than to pharmacological effects of reboxetine itself on
central nervous serotonergic metabolism.
We evaluated the intensity dependence of various auditory ERP components in
MDD before and after a mean period of 25 days and 24 days of treatment,
respectively, with either the selective serotonin reuptake inhibitor citalopram or
the selective norepinephrine reuptake inhibitor reboxetine, and compared these
results with that of a healthy control group.
The results of our investigations did not confirm our hypotheses, because they
suggest that neither serotonergic medication with citalopram nor treatment
effects as measured by an increase in the HDRS total score in the reboxetine
treatment subgroup had a significant effect on the IDAP derived from the N1,
P1/N1 and N1/P2 ERP components during the course of treatment. However, we
found significant 3-way (treatment group x time x intensity) interaction effects at
electrodes Cz and C3 with regard to the P2 component. These were due mainly to
a decrease in P2 intensity slopes over time in the reboxetine group. Considering
that our group did not find the P2 component of relevance in the prediction of
antidepressant treatment efficacy, this result was unexpected. There are,
however, previous reports on P2 effects (Paige, 1994), showing higher pre-
treatment P2 intensity slopes to be associated with positive treatment responses
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to SSRIs. With regard to the small sample sizes in the treatment subgroups, our P2
results should be replicated in a larger sample of patients. Our data indicate that
during the course of treatment, the N1 component seems to be more stable than
the P2. In our data, the N1 amplitude slope at electrode Fz was significantly
correlated with the N1/P2 (r=.57, p<.001), with the P1/N1 (r=.65, p>.001), but to a
much lower degree with the P2 (r=.32, p=.043) slopes. We suggest that in our
experimental set-up the N1 is the most sensitive variable. This is in line with our
previous reports using the same experimental protocol (Linka et al., 2004; Linka et
al., 2005).
Our relatively small patient samples are an important limitation of our studies.
Further limitations result from the open-label and treatment-as-usual design of
our studies. These limitations were due to the ethical problems that a double-blind
randomized design with fixed doses of the applied antidepressants brings about in
the research with patients, who suffer from clinically relevant depressive
disorders.
The observed lack of treatment effects on the IDAP might indicate that the IDAP is
a rather trait than a state parameter of central nervous serotonergic transmission.
This conclusion is in line with several studies which demonstrated a considerable
degree of heritability of the IDAP (Sandor et al., 1999) and reported an association
of the IDAP with 5-HTTLPR, a genetic polymorphism of the serotonin transporter
coding gene (Gallinat et al., 2003;Hensch et al., 2006; Strobel et al., 2003).
Moreover, our results are in accordance with those obtained in recent studies by
Guille et al. (2008), who found no effects of acute treatment with various SSRIs on
the IDAP, and by Norra et al. (2008), who found no correlation of the IDAP with
acute tryptophan depletion and with states of mood in healthy subjects.
4. The IDAP in unmedicated patients with MDD and in healthy
controls
The presented study was designed to compare the IDAP in unmedicated depressed
patients with that of healthy control subjects, in order to answer the question
whether there is a general abnormality of the IDAP in MDD. We therefore
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evaluated the change of auditory evoked P1, N1, P2, as well as P1/N1 and N1/P2
peak to peak amplitudes, in 34 in-patients with MDD prior to antidepressant
treatment, and in 44 healthy control subjects. In multivariate analyses of variance,
no group differences in the IDAP of the P1, N1, P2 and of the P1/N1 and N1/P2
peak to peak amplitudes between patients and controls were detected.
Although, compared to patients, controls showed a slightly higher intensity
dependent amplitude increase at Cz, in an overall analysis of electrodes Fz, FCz, Cz,
C3, C4, we found no significant group differences. Given the sample size and
compared to the highly significant predictive power of the IDAP with regard to
treatment outcome (Gallinat et al., 2000; Lee et al., 2005; Linka et al., 2004; Linka
et al., 2005), the IDAP baseline differences between patients and controls at Cz
were small and after adjustment for multiple testing (Bonferoni) turned out to be
non-significant.
We performed analyses based on five commonly used methods in the calculation
of amplitudes (P1/baseline, N1/baseline, P2/baseline, P1/N1, N1/P2). The intensity
dependent amplitude slopes of the subjects in our study can be compared to those
obtained in previous studies using similar procedures and measures. Therefore, it
can be concluded that results from our experimental setup are comparable to
previously reported results assessing healthy subjects with similar methods and
that the lack of significant differences in auditory evoked potentials between
patients with major depression and matched healthy control subjects is unlikely to
be related to methodological factors.
Our data revealed no general abnormality of the IDAP in patients with major
depression in comparison to healthy control subjects. The lack of such a difference
between patients and controls in our study, seems to be contradictory to the
studies that support the significance of the IDAP as a clinically relevant indicator of
the central nervous serotonergic dysfunction in depressive disorders. In our study,
variances of the IDAP were only slightly larger in patients than in controls. It can be
assumed that a subgroup of controls as well as MDD patients show some kind of
dysregulation of the serotonergic system. Considering the results from Methylen-
Diethyl-Metamfetamine (MDMA, ecstasy)-users (Croft et al., 2001; Tuchtenhagen
et al., 2000) and the inverse association between IDAP and the serotonin
syndrome (Hegerl et al., 1998), it is very likely that the IDAP reflects the sensitivity
of the central serotonergic system. On the other hand, the IDAP allows indirect
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conclusions as to the sensitivity to noradrenergic antidepressants considering an
assumed imbalance of NE- and 5-HT neurotransmitter systems as a relevant
pathophysiological factor in MDD. The results of our study do not necessarily
contradict the assumed role of the IDAP as an indicator a central nervous
serotonergic sensitivity in MDD and other psychiatric disorders, but suggests that
specific alterations of the IDAP are not to be expected in MDD in general. Such
differences may be confined to subgroups of depressed patients. The
phenomenon that only a subgroup of depressed individuals shows associations
with a biological factor that is assumed to reflect serotonergic sensitivity is also
known from genetic approaches, e.g. such as from serotonin transporter
polymorphism studies.
These finding indicate that in the clinical practice, the IDAP might be useful to
identify patients suffering from MDD who are more likely to respond to SSRI
treatment.
5. Clinical symptoms of major depression are associated with the
intensity dependence of auditory ERP components
The purpose of this study was to investigate whether the IDAP is associated with
certain patterns of psychometrically assessed symptoms of depression. The study
aimed to identify, describe and discuss those psychometric syndromes, which
might thus indirectly be associated with a favourable outcome to SSRI treatment
as predicted by a strong IDAP.
We assessed 40 in-patients with MDD prior to antidepressant treatment.
Psychometric characteristics of depression were assessed by means of broadly
accepted psychiatric rating scales (HDRS, BDI, HAMA, STAI and CGI) and the results
were subsequently evaluated for associations with auditory evoked P1, N1, P2, as
well as P1/N1 and N1/P2 peak to peak amplitude slopes.
Seven rating scale items (HAMA “Depressed Mood”, BDI “Lack of interest in sex“,
HDRS “insomnia, early“ and “decreased libido or menstrual disturbance”, BDI
“hopelessness” and “decreased appetite”, and the HDRS item “weight loss”)
correlated with more than r = 0.2 with the IDAP. The correlation coefficient of the
General discussion
-136-
composite score of these 7 items was statistically highly significant with r = .64.
The composite score can be viewed at as a construction of a kind of questionnaire
derived from the pool of questions obtained in our study. The fact, that the
correlation of the composite score with the N1 amplitude slope was considerably
higher than each of the correlations with the single items, may be considered as
indirect evidence for the relevance of the selected items. The first four of these
single items (HAMA “Depressed Mood”, BDI “Lack of interest in sex“, HDRS
“insomnia, early“ and “decreased libido or menstrual disturbance”) correlated
significantly with the IDAP whereas the remaining three (BDI “hopelessness” and
“decreased appetite”, and the HDRS item “weight loss”) showed a statistical trend
towards significance only. Of special relevance were the items that identified
congruent symptom severity on both the external rating (HDRS) as well as the
patient’s self-rating (BDI). It concerned the HDRS item “decreased libido or
menstrual disturbance” and BDI item “lack of interest in sex” , as well as the HDRS
item “weight loss” and BDI item “decreased appetite”.
Of special clinical interest is the finding that a high score of sexual disturbance on
the BDI, as well as on the HDRS, was associated with a high IDAP, considering that
a high IDAP correlates with a favourable response to SSRI-treatment (Gallinat et
al., 2000; Paige et al., 1994). The presence of sexual dysfunction associated with
depression has so far not been described as a criterion for pharmacotherapy with
an SSRI. However, these observations seem to be in contrast to a study suggesting
a beneficial treatment effect of reboxetine in depressive patients with sexual
dysfunction (Clayton et al., 2003). In line with the latter result, many clinicians
tend to avoid SSRIs in the treatment of major depression associated with sexual
disturbances. On the other hand, Cyranowksi et al. (2004) found that SSRI-induced
sexual dysfunction in a group of 68 women treated for recurrent MDD, was
restricted to orgasmic difficulties only, whereas libido and sexual interest were
related to depression itself. As a consequence of our findings, future studies might
evaluate the hypothesis that the existence of sexual dysfunction (apart from
orgasmic difficulty) in MDD may be an additional criterion that favours the
treatment with SSRIs.
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6. Conclusions
In two clinical studies we were able to demonstrate the predictive value of the
IDAP in differentiating antidepressant treatment: A high pre-treatment IDAP was
shown to be associated with a favourable treatment outcome to the SSRI
citalopram, whereas a low pre-treatment IDAP appeared to coincide with an
increased treatment effect to the SNRI reboxetine in MDD. These results
corroborated the concept of the IDAP as a non-invasive, clinically applicable pre-
treatment indicator of central nervous serotonergic neurotransmission. Moreover,
the association between IDAP and reboxetine response suggested that the IDAP
may also reflect a disturbed serotonin/norepinephrine balance in the central
nervous system.
Neither serotonergic nor non-serotonergic antidepressants were found to induce
significant alterations in the IDAP. Furthermore, the IDAP did not significantly
change during the course of treatment of MDD and, as such, was not influenced by
clinically observed changes of depressive symptoms. These results indicated that
the IDAP does not reflect depressive states but is more likely a trait indicator of
central serotonergic neurotransmission. The latter conclusion implies that
treatment-success in MDD is unlikely to bring about a “normalization” of the IDAP.
Although we expected a lower central nervous serotonergic neurotransmission in
depression, we were not able to detect a general abnormality of the IDAP in MDD.
Therefore, we concluded that a pre-treatment abnormality of the IDAP might be
confined to a specific subgroup of MDD. In line with this hypothesis, we found
associations of a strong libido decrease, sexual dysfunction, loss of appetite and
weight with a strong IDAP.
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STIMULUS INTENSITY DEPENDENT ERP COMPONENTS IN THE
PHARMACOTHERAPY OF MAJOR DEPRESSIVE DISORDER
Major depressive disorder (MDD) belongs to the most common mental diseases in
Europe and in the United States. The multifactorial etiology of depression is widely
accepted, but the contributional value of psychosocial, neurobiological and genetic
factors remains unclear. Heritability of major depression probably ranges from
31% to 41%. Disturbances in various neuroendocrine and neurotransmitter
systems have been associated with the pathophysiological mechanisms, which are
assumed to contribute to the origin of depressive disorders. Particularly the
discussion of the role of the monoaminergic system and the hypothalamic-
pituitary-adrenal axis has a long tradition. The etiologic impact of stressful life
events, economic status, social relationships and personality on depressive
disorders has been investigated extensively, but there are hardly theoretic
concepts which have been widely accepted.
Despite significant advances in the pharmacological treatment of depressive
disorders over the past 20 years, many patients (28 - 55%) fail to respond
sufficiently to the treatment with the newer serotonin re-uptake inhibitor (SSRI)
antidepressants. That is why reliable prediction methods of treatment response to
serotonergic versus non-serotonergic antidepressants could be of considerable
clinical value.
Electroencephalography (EEG) is a diagnostic method based on the measurement
of electrical activity produced by the brain as recorded from electrodes placed on
the scalp. Cognitive research conducted with the EEG frequently uses the event-
related potential (ERP) technique. Preclinical and clinical studies indicate that a
high intensity (loudness) dependent amplitude increase (“high intensity
dependence”, “high IDAP”) of auditory evoked potentials seems to reflect a low
central nervous serotonergic neurotransmission and vice versa. This hypothesis
has been confirmed in animal and human studies.
The major aims of this thesis were to evaluate the predictive value of pre-
treatment IDAP in MDD under treatment with either the SSRI citalopram or with
the SNRI reboxetine, to investigate whether the IDAP is mainly a state or a trait
indicator of central serotonergic neurotransmission. In addition, it was studied
whether serotonergic and non-serotonergic antidepressants differently influence
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the IDAP and whether the IDAP changes during the course of treatment of MDD.
Furthermore, the hypothesis was addressed that unmedicated individuals
suffering from major depression exhibit a higher IDAP compared to healthy control
subjects and that this is associated with certain patterns of psychometrically
assessed symptoms of depression.
In chapter 2, we report the results of a study evaluating the IDAP in 16 in-patients
fulfilling the DSM-IV criteria for major depressive episode during treatment with
the SSRI citalopram. Our data revealed a significant correlation between the
intensity slopes of the N1 amplitude prior to citalopram-treatment and treatment-
response: patients with higher intensity slopes of N1 amplitude showed a
significantly stronger decrease of HDRS-Score after citalopram-treatment than
patients within the lower intensity slope ranges.
In chapter 3, we present the first study to assess the predictive value of the IDAP
in SNRI treatment. We evaluated the pre-treatment intensity dependent change of
auditory evoked P1, N1, P2, as well as P1/N1 and N1/P2 peak to peak amplitudes,
in 14 in-patients with major depressive episode (DSM IV criteria) during the course
of 24 days of treatment with the SNRI reboxetine (6 to 12 mg/d). Our data
revealed a highly significant correlation between lower intensity dependent N1
amplitude slopes prior to reboxetine treatment and a stronger decrease of the
HDRS total score at Fz (r=.86, p<.001), FCz (r=.91, p<.001) and Cz (r=.93, p<.001).
In chapter 4, we describe a study that aimed to compare the IDAP in unmedicated
depressed patients with that of healthy control subjects. We evaluated the change
of auditory evoked P1, N1, P2, as well as P1/N1 and N1/P2 peak to peak
amplitudes, in 34 in-patients with a major depressive episode (DSM-IV criteria)
prior to antidepressant treatment, and 44 healthy control subjects. In multivariate
analyses of variance, we found no group differences in the intensity dependent
increase, neither of the P1, N1, and P2, nor of the P1/N1 and N1/P2 peak to peak
amplitudes, between patients and controls.
In chapter 5, we present a study that aimed to evaluate associations between
clinical symptoms of major depression and the IDAP as an indirect indicator of
serotonergic function in the cortex. We assessed 40 in-patients suffering from a
major depressive episode (DSM-IV criteria) prior to antidepressant treatment.
Psychometric characteristics of depression were assessed by means of psychiatric
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rating scales (HDRS, BDI, HAMA, STAI and CGI) and evaluated for associations with
auditory evoked P1, N1, P2, as well as P1/N1 and N1/P2 peak to peak amplitude
slopes. Our data revealed a positive correlation of the intensity dependent N1
amplitude slope with the degree of certain somatic symptoms of depression: libido
decrease and sexual dysfunction, loss of appetite and weight and insomnia.
Chapter 6 deals with a study that measured the IDAP in major depressive disorder
(MDD) before and after treatment with either a selective serotonin reuptake
inhibitor or a selective norepinephrine reuptake inhibitor antidepressant and
compared the results with that of a healthy control group. Auditory evoked P1, N1,
P2, P1/N1 and N1/P2 peak to peak amplitudes were evaluated in 26 in-patients
with MDD prior to and after antidepressant treatment with citalopram (24 days,
n=14) or reboxetine (25 days, n=12), and 43 healthy control subjects. Neither
antidepressants nor decrease in the HDRS total score had a significant effect on
the IDAP. These results suggested that the IDAP is rather a trait than a state
indicator of serotonergic neurotransmission in MDD.
In chapter 7 we discuss the results and present the final conclusions of this thesis.
Our results indicate an association of N1 amplitude intensity dependence with
response to antidepressant treatment with citalopram and reboxetine: a high IDAP
predicts better treatment outcome with SSRIs like citalopram, whereas a low IDAP
is associated with better outcome to reboxetine treatment. Our data revealed no
general abnormality of the IDAP in patients with major depression in comparison
to healthy control subjects. This result suggested that specific alterations of the
IDAP are not to be expected in major depression in general, but that these may be
confined to subgroups of depressed patients. Our data revealed a positive
correlation of the intensity dependent N1 amplitude slope with the degree of
certain somatic symptoms of depression. As neither antidepressants nor decrease
in the HDRS total score had a significant effect on the IDAP, we conclude that the
IDAP is rather a trait than a state indicator of serotonergic neurotransmission in
MDD.
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STIMULUS INTENSITEIT AFHANKELIJKE ERP COMPONENTEN BIJ DE
BEHANDELING VAN DEPRESSIEVE STOORNISSEN
Depressieve stoornissen (Major Depressive Disorder; MDD) behoren tot de meest
voorkomende psychiatrische ziekten in Europa en de Verenigde Staten. De
multifactoriële etiologie van depressie is algemeen aanvaard, maar de etiologische
waarde van psychosociale, neurobiologische en genetische factoren, blijft
onduidelijk. De erfelijke component van depressies varieert waarschijnlijk van 31%
tot 41%. Verstoringen in verschillende neuroendocriene en neurotransmitter
systemen zijn geassocieerd met de pathofysiologische mechanismen, die geacht
worden bij te dragen aan de oorsprong van depressieve stoornissen. Vooral de
bespreking van de rol van het monoaminerge systeem en de hypothalamus-
hypofyse-bijnier as heeft een lange traditie. De etiologische gevolgen van
stressvolle gebeurtenissen in het leven, economische situatie, sociale relaties en
persoonlijkheid op depressieve stoornissen zijn uitvoerig onderzocht, maar er zijn
nauwelijks theoretische concepten die algemeen aanvaard zijn.
Ondanks de aanzienlijke vooruitgang in de farmacologische behandeling van
depressieve stoornissen in de afgelopen 20 jaar, reageren veel patiënten (28 -
55%) niet voldoende op de behandeling met de nieuwere serotonine heropname
remmer (SSRI) antidepressiva. Dat is de reden waarom een betrouwbare
voorspelling van de effectiviteit van de behandeling, met serotonerge versus niet-
serotonerge antidepressiva, van aanzienlijke klinische waarde zou kunnen zijn.
Electroencephalografie (EEG) is een diagnostische methode gebaseerd op het
meten van de elektrische activiteit die ontstaat in de hersenen en wordt afgeleid
via elektroden op de hoofdhuid. Cognitief onderzoek uitgevoerd met deze EEG
methode maakt vaak gebruik van de gebeurtenis gerelateerde potentialen (Event
Related Potentials; ERP) techniek. Uit preklinische en klinische studies blijkt dat
een hoge intensiteit (volume) afhankelijke amplitude stijging ( "hoge intensiteit
afhankelijkheid", "hoge IDAP") van auditief opgewekte potentialen een lage
neurotransmissie van serotonine in het centrale zenuwstelsel lijkt te
weerspiegelen en vice versa. Deze hypothese werd bevestigd in dierexperimenteel
onderzoek en in humane studies.
De belangrijkste doelstellingen van dit proefschrift waren: a. wat is de
voorspellende waarde van de IDAP in het kader van de behandeling met de SSRI
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citalopram of met de selectieve noradrenaline heropname remmer (SNRI)
reboxetine bij patiënten met een MDD en b. is de IDAP vooral een state of een
trait-indicator van de centrale serotonerge neurotransmissie. Daarnaast werd
onderzocht of serotonerge en niet-serotonerge antidepressiva verschillend van
invloed zijn op de IDAP en of de IDAP veranderingen ondergaat in de loop van de
behandeling van de MDD. Tenslotte werd de hypothese getoetst of niet
medicamenteus behandelde personen die lijden aan een ernstige depressie een
hogere IDAP vertonen in vergelijking met gezonde controle personen en of dit dit
in verband gebracht kan worden met bepaalde patronen van psychometrisch
beoordeelde symptomen van depressie.
In hoofdstuk 2 worden de resultaten van een studie ter evaluatie van de IDAP met
16 opgenomen patiënten die voldoen aan de DSM-IV criteria voor ernstige
depressieve episode tijdens de behandeling met de SSRI citalopram beschreven.
Uit onze gegevens bleek een significante correlatie te bestaan tussen de intensiteit
afhankelijke stijging van de N1 amplitude voorafgaand aan citalopram behandeling
en behandelrespons: patiënten met een hogere intensiteit afhankelijke stijging van
de N1 amplitude vertoonden een significant sterkere daling van de ernst van de
depressie (HDRS-Score) na citalopram behandeling dan patiënten met lagere
intensiteit afhankelijke toename van de N1 amplitude.
In hoofdstuk 3 presenteren wij de eerste studie naar de voorspellende waarde van
de IDAP bij SNRI behandeling met reboxetine. Hiertoe werden de intensiteit
afhankelijke veranderingen van voorafgaand aan de medicatie auditief opgewekte
P1, N1, P2, evenals P1/N1 en N1/P2 piek tot piek amplituden, bij 14 opgenomen
patiënten met een ernstige depressieve episode (DSM-IV criteria) geëvalueerd in
de loop van 24 dagen van een behandeling met de SNRI reboxetine (6 tot 12 mg /
d). Uit onze gegevens bleek een hoog significante correlatie te bestaan tussen een
lagere intensiteit afhankelijke toename van de N1 amplitude [Fz (r =. 86, p <.001),
FCz (r =. 91, p < .001) en CZ (r =. 93, p <.001)] voorafgaand aan de behandeling met
reboxetine en een sterkere daling van de totale score op HDRS.
In hoofdstuk 4 beschrijven wij een studie die gericht is op een vergelijking van de
IDAP bij niet medicamenteus behandelde depressieve patiënten met die bij
gezonde controlepersonen. De verandering van auditief opgewekte P1, N1, P2,
evenals P1/N1 en N1/P2 piek tot piek amplituden, werd geëvalueerd bij 34 in-
patiënten met een ernstige depressieve episode (DSM-IV criteria) voorafgaand aan
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de behandeling met een antidepressivum, en 44 gezonde controlepersonen. In de
multivariate analyses van de variantie, vonden wij geen enkel groepverschil tussen
de patiënten en de controles in de intensiteit afhankelijke stijgingen, noch van de
P1, N1, en P2, noch van de P1/N1 en N1/P2 piek tot piek amplituden.
In hoofdstuk 5 presenteren wij een onderzoek dat gericht is op het evalueren van
associaties tussen klinische symptomen van een depressie en de IDAP als een
indirecte indicator van serotonerge functie in de cortex. Veertig patiënten met een
ernstige depressieve episode (DSM-IV criteria) werden onderzocht voorafgaand
aan behandeling met een antidepressivum. Psychometrische kenmerken van de
depressie werden beoordeeld aan de hand van gestandaardiseerde
beoordelingsschalen (HDRS, BDI, HAMA, STAI en CGI) en geëvalueerd voor
associaties met auditief opgewekte P1, N1, P2, evenals P1/N1 en N1/P2 piek tot
piek amplitude stijgingen. Uit onze gegevens bleek een positieve correlatie tussen
de intensiteit afhankelijke N1 amplitude stijging met de graad van bepaalde
somatische symptomen van depressie: daling van libido en seksuele disfunctie,
verlies van eetlust en gewicht en slapeloosheid.
Hoofdstuk 6 beschrijft een onderzoek naar de gemeten IDAP bij depressieve
stoornissen (MDD) vóór en na behandeling met een selectieve serotonine
heropname remmer of een selectieve noradrenaline heropname remmer en
vergelijkt de resultaten met die verkregen van een gezonde controle groep.
Auditief opgewekte P1, N1, P2, P1/N1 en N1/P2 piek tot piek amplituden werden
geëvalueerd bij 26 patiënten met MDD voorafgaand aan en na de behandeling met
de antidepressiva citalopram (24 dagen, n = 14) of reboxetine (25 dagen, n = 12),
en 43 gezonde controlepersonen. Geen van beide behandelstrategieën, noch een
afname van de totale score op de HDRS, had een significant effect op de IDAP.
Deze resultaten suggereren dat de IDAP eerder als een trait dan als een state
indicator van serotonerge neurotransmissie kan worden beschouwd bij patiënten
met MDD.
In hoofdstuk 7 bespreken wij de resultaten en worden samenvattende conclusies
geformuleerd. Onze resultaten wijzen op een associatie van N1 amplitude
intensiteit afhankelijkheid met de respons op een behandeling met de
antidepressiva citalopram of reboxetine: een hoge IDAP voorspelt betere
behandelresultaten met SSRI's, zoals citalopram, terwijl een lage IDAP
geassocieerd is met een beter resultaat met reboxetine behandeling. Uit onze
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gegevens bleek geen algemene afwijking van de IDAP bij patiënten met depressie
in vergelijking met gezonde controlepersonen. Dit resultaat wijst erop dat
specifieke wijzigingen van de IDAP bij een depressie in het algemeen niet zijn te
verwachten, maar dat deze beperkt zijn tot bepaalde subgroepen van depressieve
patiënten. Uit onze gegevens bleek namelijk een positieve correlatie tussen de
intensiteit afhankelijke N1 amplitude stijging met de ernst van bepaalde
somatische symptomen van een depressie. Aangezien noch antidepressiva, noch
een daling van de totale score op de HDRS een significant effect had op de IDAP,
concluderen wij dat de IDAP eerder als een trait dan als een state indicator van
serotonerge neurotransmissie in MDD moet worden beschouwd.
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LAUTSTÄRKEABHÄNGIGE ERP KOMPONENTEN IN DER
PHARMAKOTHERAPIE DEPRESSIVER STÖRUNGEN
Depressive Störungen (Major Depressive Disorder, MDD) gehören zu den
häufigsten psychischen Erkrankungen in Europa und den Vereinigten Staaten. Die
multifaktorielle Ätiologie depressiver Störungen ist weithin anerkannt, aber die
genaue ätiologische Bedeutung von psychosozialen, neurobiologischen und
genetischen Faktoren nach wie vor unklar. Der Einfluss genetischer Faktoren wird
auf 31% bis 41% geschätzt. Vor allem Störungen in neuroendokrinen und
Neurotransmitter-Systemen werden im Zusammenhang mit den
pathophysiologischen Mechanismen, die zur Entstehung depressiver Erkrankungen
beitragen, diskutiert. Vor allem die Diskussion über die Rolle der Monoamine und
der Hypothalamus-Hypophysen-Nebennieren-Achse hat eine lange Tradition. Die
Auswirkungen von belastenden Lebensereignissen, der wirtschaftliche Situation,
sozialer Beziehungen und von Persönlichkeitsfaktoren auf die Entstehung und
Manifestation depressiver Störungen wurden vielfach untersucht, aber es gibt
diesbezüglich nur wenig allgemein akzeptierte theoretische Konzepte.
Trotz der erheblichen Fortschritte in der pharmakologischen Behandlung von
depressiven Erkrankungen in den letzten 20 Jahren respondieren viele Patienten
(28 bis 55%) nicht oder nicht ausreichend auf die Behandlung mit den neueren
Serotonin-Wiederaufnahmeaufnahme-Hemmstoffen (SSRI). Das ist der Grund,
weshalb zuverlässige Vorhersagemethoden der individuell anzunehmenden
Effektivität serotonerger und nicht-serotonerger Antidepressiva wesentliche
klinische Bedeutung zukommen kann.
Die Elektroenzephalografie (EEG) ist eine diagnostische Methode, bei der die
elektrische Aktivität im Gehirn über Elektroden auf der Kopfhaut abgeleitet und
gemessen wird. Kognitive Forschungsansätze unter Einsatz des EEGs machen
häufig Gebrauch von sogenannten Ereigniskorrelierten Potentialen (Event Related
Potentials, ERP). Präklinische und klinische Studien haben ergeben, dass ein
verstärkter lautstärkeabhängiger Amplitudenanstieg (= hohe Intensitäts-
abhängigkeit, hohe IDAP) von akustisch (auditorisch) evozierten Potentialen mit
einer relativ geringen Transmission von Serotonin im zentralen Nervensystem
assoziiert ist. Diese Assoziation gilt offenbar auch umgekehrt (niedriger,
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lautstärkeabhängiger Amplitudenanstieg entspricht hoher zentralnervöser
Serotoninaktivität). Diese Hypothese wurde in Tierversuchen und in Studien am
Menschen belegt.
Die wichtigsten Fragestellungen der vorliegenden Untersuchungen lauteten: a.
Welcher klinische Vorhersagewert kommt der IDAP in der Differentialindikation
des SSRI Citalopram und des NRI Reboxetin bei Patienten mit depressiven
Störungen zu? und b. Ist die IDAP vor allem ein State- oder eher ein Trait-Indikator
der zentralnervösen serotonergen Transmission bei MDD? Auch wurde
untersucht, ob serotonerge und nicht-serotonerge Antidepressiva signifikant
unterschiedliche Auswirkungen auf die IDAP haben und ob die IDAP während der
Behandlung der MDD Veränderungen unterliegt. Darüber hinaus wurde die
Hypothese geprüft, dass nicht medikamentös behandelte Personen mit MDD eine
höhere IDAP im Vergleich zu gesunden Kontrollpersonen aufweisen. Schließlich
wurde der Zusammenhang zwischen bestimmten Gruppen psychometrisch
bewerteter Symptome der Depression und der IDAP evaluiert.
In Kapitel 2 werden die Ergebnisse einer Studie zur Beurteilung der IDAP bei 16
Patienten, die die DSM-IV-Kriterien für eine MDD-Episode erfüllten, in der
Behandlung mit dem SSRI Citalopram beschrieben. Unsere Daten zeigen eine
signifikante Korrelation zwischen dem lautstärkeabhängigen Anstieg der N1-
Amplitude vor Beginn der Citalopram-Behandlung und der klinischen Response:
Patienten mit einem höheren lautstärkeabhängigen Anstieg der N1 Amplitude
zeigten eine signifikant stärkere Abnahme der Schwere der Depression (HDRS --
Ergebnis) nach Citalopram-Behandlung als Patienten mit geringerem
lautstärkeabhängigem Anstieg der N1-Amplitude.
In Kapitel 3 haben wir die erste Studie zur prädiktiven Aussagekraft der IDAP in der
Behandlung mit einem SNRI-Antidepressivum dargestellt. Die Intensitäts-
abhängigkeit der auditorisch evozierten P1-, N1-, P2-, und P1/N1- und N1/P2-
Amplituden (peak-to-peak) wurde bei 14 Patienten einer MDD-Episode (DSM-IV-
Kriterien) vor und nach der durchschnittlich 24-tägigen Behandlung mit dem SNRI
Reboxetin (6-12 mg / d) erfasst. Es ergab sich eine signifikante Korrelation
zwischen einem geringeren lautstärkeabhängigen Anstieg der N1-Amplitude [Fz (r
=. 86, p <.001), FCz (r =. 91, p <.001) und Cz (r =. 93, p <.001)] vor
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Behandlungsbeginn und einer deutlicheren Minderung des HDRS-Gesamtwertes
nach erfolgter Behandlung mit Reboxetin.
In Kapitel 4 beschreiben wir eine Studie, die die IDAP bei nicht medikamentös
behandelten Patienten mit MDD mit der IDAP bei gesunden Kontrollpersonen
vergleicht. Es wurden auditorisch evozierte P1-, N1-, P2-, und P1/N1- und N1/P2-
Amplituden (peak-to-peak) bei 34 Patienten mit einer MDD-Episode (DSM-IV-
Kriterien) vor Behandlungsbeginn mit einem Antidepressivum und bei 44
gesunden Kontrollpersonen miteinander verglichen. In der multivariaten
Varianzanalyse, fanden sich keine Gruppenunterschied zwischen Patienten und
Kontrollen weder im Hinblick auf die Intensitätsabhängigkeit der P1-, N1- und P2-,
noch auf die IDAP der P1/N1- und N1/P2- Amplitude.
In Kapitel 5 stellen wir eine Studie zur Bewertung der Zusammenhänge zwischen
den klinischen Symptomen der Depression und der IDAP als indirektem Indikator
der zentralnervösen serotonergen Transmission vor. Vierzig Patienten mit einer
MDD-Episode (DSM-IV-Kriterien) wurden vor der Behandlung mit einem
Antidepressivum untersucht. Psychometrische Merkmale der Depression wurden
mit standardisierten Rating-Skalen (HDRS, BDI, HAMA, STAI und CGI) bewertet und
im Hinblick auf Assoziationen mit Lautstärkeabhängigkeit von auditorisch
evozierten P1-, N1-, P2-, P1/N1- und N1/P2-Amplitude (peak-to-peak) evaluiert.
Die Ergebnisse weisen auf eine positive Korrelation zwischen der
Intensitätsabhängigkeit der N1-Amplitude und dem Ausprägungsgrad bestimmter
somatischer Symptome der Depression hin: Libidoverlust und sexuelle
Dysfunktion, Appetitmangel und Gewichtsverlust sowie Schlaflosigkeit.
Kapitel 6 beschreibt eine Studie, die die IDAP bei depressiven Störungen (MDD)
vor und nach der Behandlung entweder mit einem SSRI oder einem SNRI erfasste
und die Ergebnisse mit denen einer gesunden Kontrollgruppe verglich. Auditiv
evozierte P1-, N1-, P2, P1/N1- und N1/P2- Amplituden wurden bei 26 Patienten
mit MDD vor und nach der Behandlung mit den Antidepressiva Citalopram (24
Tage, n = 14) oder Reboxetin (25 Tage, n = 12) und bei 43 gesunden
Kontrollpersonen gemessen. Weder die verabreichten Antidepressiva noch eine
Verminderung der HDRS-Gesamtwertes hatten signifikante Auswirkungen auf die
Höhe der IDAP. Diese Ergebnisse deuten darauf hin, dass die IDAP eher ein Trait-
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als State-Indikator der serotonergen Neurotransmission bei Patienten mit MDD
sein könnte.
In Kapitel 7 diskutieren wir die Ergebnisse und zusammenfassenden
Schlussfolgerungen dieser Dissertation. Unsere Ergebnisse legen eine Assoziation
der Intensitätsabhängigkeit vor allem der N1-Amplitude mit der Therapieresponse
auf eine Behandlung mit den Antidepressiva Citalopram und Reboxetin nahe: eine
hohe IDAP prognostiziert bessere Behandlungsergebnisse mit SSRI wie Citalopram,
während eine niedrige IDAP mit einem günstigeren Effekt bei Reboxetin-
Behandlung assoziiert ist. Unsere Daten zeigten insgesamt keine signifikanten
Unterschiede der IDAP bei Patienten mit depressiven Störungen (MDD) im
Vergleich mit gesunden Kontrollpersonen. Dieses Ergebnis deutet darauf hin, dass
eine pathologische Abweichung der IDAP bei depressiven Störungen im
Allgemeinen nicht besteht. Möglicherweise spezifische Veränderungen IDAP sind
allenfalls bei gegebenenfalls pathophysiologisch definierbaren Untergruppen
depressiver Störungen zu erwarten. Unsere Ergebnisse weisen außerdem auf eine
positive Korrelation zwischen der Intensitätsabhängigkeit der N1-Amplitude und
der Schwere einiger somatischer Symptome bei MDD hin. Da bei unseren
Untersuchungen weder die verabreichten Antidepressiva noch eine Reduktion des
HDRS-Gesamtwertes eine signifikante Auswirkung auf die Höhe der IDAP hatte,
kommen wir zu dem Schluss, dass die IDAP vornehmlich als Trait- nicht jedoch als
State-Indikator der serotonergen Neurotransmission bei MDD betrachtet werden
kann.
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